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ABSTRACT 
The pathogenetic mechanisms underlying type 2 diabetes (T2D) and prediabetes involve an 
interaction between β-cell dysfunction and insulin resistance (IR). The resulting 
hyperglycemia, as well as other clustered cardiovascular (CV) risk factors in T2D, constitutes 
a severe hazard for development of complications to the disease. To optimally treat these risk 
factors, it is vital to antagonize the mechanisms of the metabolic disorder. This thesis presents 
results from studies aiming to understand the mechanisms and effects of some interesting 
modes of intervention in subjects with T2D, prediabetes and IR. 
Study I: The effects of exercise training for twelve weeks, with or without the addition of the 
α-glucosidase inhibitor acarbose, were examined in 48 subjects with T2D and moderate 
hyperglycemia. Exercise training augmented insulin sensitivity, and improved body 
composition and blood pressure, but glycemic control was unchanged. When exercise and 
acarbose were combined, glycemic control was significantly improved, in addition to similar 
benefits as with exercise alone.  Moreover, the overall CV risk factor profile was probably 
improved with the combination therapy, suggesting it to be an interesting treatment 
alternative. 
Study II: The associations between changes in mRNA expression in skeletal muscle of 
selected key genes, involved in muscle adaptation to exercise, and individual response to 
physical training were assessed in 19 individuals from study I. The expression of vascular 
endothelial growth factor (VEGF) was associated with change in insulin sensitivity and 
glycemic control. This could constitute a mechanism that contributes to the known variation 
in the individual adaptation to exercise. 
Study III: The impact of dual endothelin-1 (ET-1) receptor blockade infusion was 
investigated in eleven males with IR. The study showed that the dual blockade increased 
glucose uptake in skeletal muscle, both in the basal and the insulin-stimulated state. The 
finding supports that endogenous ET-1 is important in regulating muscle glucose uptake in 
IR. Moreover, in vitro studies in cultured skeletal muscle cells demonstrated that ET-1 
inhibits glucose uptake by a receptor dependent mechanism, indicating a direct impact on 
muscle cells by ET-1. 
Study IV: Intervention with high-dose vitamin D3 treatment for eight weeks was studied in 
43 individuals with prediabetes or drug-naïve T2D, especially with respect to change in β-cell 
function. No significant effect was seen in first-phase insulin secretion, nor could we detect 
any effects on second-phase insulin secretion, IR or glycemic control. The study gives no 
support for treatment with vitamin D in subjects with abnormal glucose homeostasis. 
In conclusion, combined treatment with exercise and acarbose proved superior to exercise 
alone. Further, a favorable response to physical training could involve increase in VEGF. In 
IR, ET-1 seems to be directly involved in muscle glucose uptake. And finally, we found no 
effect of vitamin D treatment on insulin secretion or IR in prediabetes and mild T2D. 
  
POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Mekanismerna bakom typ 2 diabetes (T2D) och förstadier till sjukdomen består av en 
kombination av minskad förmåga till insulinproduktion från bukspottskörteln och motstånd 
mot insulinets effekter i kroppen, så kallad insulinresistens. Detta orsakar förhöjt blodsocker, 
som tillsammans med andra riskfaktorer som är vanliga vid T2D, ger en påtagligt ökad risk 
för hjärtkärlsjukdom (t.ex. hjärtinfarkt och stroke). För att på bästa sett kunna behandla denna 
risk är det viktig att motverka mekanismerna bakom sjukdomen. Den här avhandlingen består 
av ett antal studier där jag har försökt förstå mekanismer och effekter av några olika 
intressanta behandlingar. Jag har undersökt dessa på personer med T2D, förstadier till 
diabetes samt hos dem med insulinresistens. 
Studie I: Jag studerade effekten av fysisk träning, med eller utan tillägg av en medicin som 
fördröjer upptaget av socker från tarmen (akarbos). Träning ensamt minskade 
insulinresistens, kroppsfett och blodtryck, men inte blodsockret. När träning kombinerades 
med akarbos såg jag samma positiva effekter, men även en sänkning av blodsockret. Troligen 
så blev flera andra riskfaktorer också bättre med den kombinerade behandlingen, som därför 
verkar vara ett intressant sätt att behandla T2D. 
Studie II: Olika personer får olika bra effekt av träning. Jag undersökte om det kunde bero av 
hur vissa gener kopplas på i musklerna. Jag fann att genen för en faktor som är viktig för att 
bilda nya kärl (VEGF) verkade vara viktig för om träningen gav mindre insulinresistens och 
bättre långtidssocker. 
Studie III: Endothelin-1 (ET-1) är ett kroppseget ämne som framförallt drar ihop kärl. 
Genom att blockera effekten av endothelin-1 kunde vi se att upptaget av blodsocker i muskler 
ökade. I odlade muskelceller minskade också ET-1 sockerupptaget, vilket tyder på att ET-1 
har en direkt effekt på cellerna. 
Studie IV: Det finns en del forskning som har talat för att D-vitamin skulle kunna påverka 
blodsockret. Jag lottade personer till en hög dos D-vitamin eller placebo (overksam medicin). 
Undersökningen kunde inte visa att D-vitamin hade någon effekt på insulinproduktion, IR 
eller blodsockerkontroll. 
Sammanfattningsvis så var kombinationsbehandling med träning och akarbos bättre än 
träning ensamt. Att få bra effekt av träning kan till viss del bero av faktorn VEGF i 
musklerna. ET-1 verkar ha en direkt effekt på blodsockerupptaget i muskelceller. Och 
slutligen så kunde jag inte se några positiva effekter av D-vitamin på mekanismer bakom 
blodsockerbalansen. 
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1 INTRODUCTION 
1.1 TYPE 2 DIABETES AND PRE-DIABETES 
Type 2 diabetes mellitus (T2D) is a state of hyperglycemia which, in combination with 
associated cardiovascular risk factors, constitutes a severe hazard of developing several health 
complications. It is by far the most common variant of diabetes, accounting for almost 90% 
of all diabetes in the world [1]. Both genetic and environmental factors are known to 
contribute to the development of the disease. Among environmental factors, obesity is 
considered the most important. In addition, physical inactivity, poor diet, tobacco and work 
stress can be mentioned among other independent risk factors [2-5]. The combination of 
heredity for T2D and obesity could be especially unfavorable, at least in men [6, 7]. 
Since hyperglycemia evolves gradually, and the fact that glucose levels just below the cut-off 
levels for T2D also are associated with increased risk of cardiovascular disease (CVD) and of 
developing manifest T2D [8, 9], pre-diabetic categories have been created. Impaired glucose 
tolerance (IGT) was acknowledged by the World Health Organization (WHO) already in 
1985, but impaired fasting glucose (IFG) much later. If IFG and IGT co-exist, the risks of 
CVD and manifest diabetes are even further increased [8]. 
1.1.1 Definitions 
The definitions and diagnosis of diabetes mellitus and pre-diabetes are based on plasma 
glucose levels. The cut-off levels have been lowered over time, in the aspiration of an earlier 
diagnosis to prevent complications. The current levels were set in 1999 [10]. Fasting plasma 
glucose levels ≥7.0 mmol/l and/or ≥11.1 mmol/l in the two-hour sample during an oral 
glucose tolerance test (OGTT) are the diagnostic cut-off levels for diabetes. Glycated 
hemoglobin (HbA1c) can also be used as a diagnostic tool according to new guidelines [11]. 
IFG is present if the fasting glucose level is 6.1-6.9 mmol/l. IGT is defined by a two-hour 
plasma glucose level of 7.8-11.0 mmol/l during an OGTT. 
1.1.2 Pathogenesis 
The pathogenesis of T2D is founded on two mechanisms: 
• Β-cell dysfunction or the insufficient capability of the β-cells in the pancreas to 
release sufficient amounts of insulin to maintain normoglycemia. 
• Insulin resistance (IR) that infers a diminished ability of insulin to exert its effects on 
different target cells, including in the liver. 
When there is a reduction in the secretion and action of insulin, the result will be a decreased 
glucose uptake in peripheral tissues, as well as an increased glucose output from the liver and 
dyslipidemia [12]. The two mechanisms contribute in different extents to hyperglycemia at 
the individual level. Further, in men with normal fasting glucose, both acute insulin response 
and IR interacted on the risk of acquiring manifest T2D 10-20 years later [13]. Moreover, 
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hyperglycemia and hyperlipidemia are hypothesized to per se further deteriorate β-cell 
function and cell responsiveness to insulin, referred as 'glucolipotoxicity' [14, 15]. 
1.1.2.1 Β-cell function 
A primary event in the disease is the reduced ability of the β-cells in the pancreas to produce 
and release sufficient amounts of insulin to maintain normoglycemia. When the insulin levels 
reached no longer can compensate for the increased demand due to IR, hyperglycemia will 
evolve. The first-phase insulin response seems to be most important in this respect [15]. The 
ability to secrete insulin decreases gradually during the course of the disease, exacerbating the 
hyperglycemic state [16]. Gene variants known to be associated with T2D are in a majority 
linked to β-cell dysfunction [17]. 
1.1.2.2 Insulin resistance 
The other major pathogenetic element in T2D is the diminished ability of insulin to exert its 
effects on different cell types in the human body. Genetic susceptibility in the combination 
with several environmental factors contribute to IR [12, 14]. The environmental factors are 
largely in common with risk factors for T2D, like abdominal and truncal obesity [18] and 
physical inactivity [19]. Further, there is evidence that IR escalates over time [20]. On a 
general level, fuel overload and decreased energy turnover have been proposed as concepts 
[14, 21]. Several mechanisms have been found to be potentially important, of which some 
will be discussed below. 
1.1.2.2.1 Skeletal muscle insulin resistance 
Skeletal muscle accounts for approximately 85% of the insulin-mediated glucose uptake in 
the human body [22] and thus constitutes the most important tissue when IR is studied. As to 
mechanisms, especially accumulation of lipid derivatives, defects in insulin signaling, as well 
as impaired blood flow in muscle are thought to contribute. Another important mechanism 
involves mitochondrial function and defects in oxidative phosphorylation [23], which will be 
discussed in the exercise section (1.2.3). Moreover, fat tissue derived adipokines and 
cytokines, such as leptin, adiponectin, interleukin-6 and tumor necrosis factor-α has attracted 
much interest in this field [14], but will not be discussed in the scoop of this thesis. 
1.1.2.2.1.1 LIP ID ACCUMULATION 
Skeletal muscle lipid content is associated to insulin resistance [24]. But muscle fat content is 
also high in well trained athletes, which have a high insulin sensitivity. This finding is 
referred to as 'the athlete paradox', and may point out that energy turnover is of greater 
importance than fat content [21]. Another related theory implicates that incomplete fat 
oxidation in the mitochondria results in mitochondrial dysfunction and subsequent IR, which 
was shown in a rodent model overfed with fat. Interestingly, exercise could reverse these 
metabolic defects [25]. Finally, several candidate pathways by which abnormalities in lipid 
metabolism could interfere with insulin signaling has been proposed [14]. 
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1.1.2.2.1.2 INSULIN SIGNALING 
The mechanisms of insulin signaling are complex. Insulin exerts its effects by binding to the 
insulin receptor. Simplified, this activates two major pathways: 1) Activation of the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-kinase) pathway, leading to increased 
translocation of the glucose transporter GLUT4 to the cell surface and increased glycogen 
synthesis, and 2) Activation of the mitogen-activated protein kinase (MAP-kinase) pathway, 
stimulating cell growth [26]. GLUT4 is recruited from intracellular storage vesicles to the 
plasma membrane. The molecular steps from the binding of insulin to the insulin receptor and 
the result of GLUT4 translocation have been extensively investigated, in the context of IR. 
Interference with signaling at three different levels have mostly been considered: 1) reduction 
in insulin receptor kinase, 2) decreased phosphorylation of insulin receptor substrate 1 
(IRS1), and 3) reduced activation of PI3-kinase [12]. Especially, interest has been focused on 
different defects at the IRS1 level in the PI3-kinase pathway, but there are data suggesting 
that defects independent of IRS1 are of importance [27, 28]. 
1.1.2.2.1.3 BLOOD FLOW 
Impaired blood flow is another corner stone in the pathogenesis of IR. If blood flow is 
reduced, the delivery of insulin and glucose to the target cells will be lower. Accordingly, 
there is an association between capillary density in human skeletal muscle and insulin 
sensitivity, measured by euglycemic clamp in non-diabetic subjects [29]. Capillary density is 
also associated with glucose tolerance [30, 31]. This suggests that the diffusion distance 
between the capillaries and muscle cells is of importance. 
However, the contribution of diminished blood flow to IR has been difficult to estimate and 
has therefore  been questioned [32]. One difficulty is that insulin per se has vasoactive 
properties and augments blood flow [33]. This is caused by a vasodilatory ability, that is 
nitric oxide (NO) dependent [34], and also by capillary recruitment [35]. In healthy men, ~ 
20-30% of the insulin-mediated glucose uptake has been estimated to depend on the 
vasodilation induced by insulin [36]. Additionally, both vasodilation and capillary 
recruitment by insulin are probably impaired in T2D [37]. But there are conflicting results in 
studies. For example, local hyperinsulinemia in healthy and hypertensive individuals did not 
increase forearm blood flow, but augmented endothelium-dependent vasodilation (Taddei, 
Virdis et al. 1995). In healthy individuals, systemic but not local hyperinsulinemia raised 
forearm blood flow, suggesting that the vasodilatory property of insulin is not only mediated 
by direct action (Cardillo, Kilcoyne et al. 1998). 
1.1.2.2.2 Hepatic insulin resistance 
An impaired hepatic ability to react to insulin, i.e. hepatic insulin resistance, will result in an 
increased endogenous glucose production by the liver. This was showed to be the most 
important factor determining the glucose excursion during an OGTT, in middle-aged men 
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with different levels of glucose tolerance [38]. As to mechanisms, accumulation of lipid 
metabolites contributes to the hepatic IR, as in muscle tissue. A main regulator is malonyl 
coenzyme A, which by inhibition of carnitine palmitoyltransferase 1 decrease the import of 
fatty acids into the mitochondria [39]. In turn, this can lead to development of non-alcohol 
hepatic steatosis, which notably can be reversed in T2D subjects by a low-fat diet and weight 
reduction [40]. 
1.1.3 Cardiovascular risk factors 
In addition to hyperglycemia, other cardiovascular risk factors such as hypertension, 
dyslipidemia and obesity are abundantly present in T2D. IR has long been regarded as the 
major underlying component of this cluster of risk factors [41]. For example, in Sweden the 
prevalence of pharmacologically treated hypertension in T2D subjects in primary care is 75% 
according to data from the National Diabetes Registry in Sweden. For dyslipidemia, the 
figure is 60% [42]. The constellation of these different elements have been considered as part 
of a syndrome, first named syndrome X by Reaven [43]. Later, the terms insulin resistance 
syndrome or metabolic syndrome became predominant. Different components have been 
proposed to be included in the syndrome by different organizations. However, the major 
components consist of hyperglycemia, abdominal obesity, hypertension and dyslipidemia – 
all independent risk factors of CVD. But the expression syndrome has been questioned by 
major opinion leaders in the field [44]. Additionally, low cardiorespiratory fitness, measured 
as maximal oxygen uptake (VO2max), is often present in T2D and is likewise an independent 
risk factor for CVD [45-47]. 
1.1.4 Complications 
Besides the complications of acute severe hyperglycemia, the major concern in T2D has been 
the late complications that often develop after several years with the disease. The major 
complications can be divided into: 
• Microangiopathy 
 Retinopathy 
 Nephropathy 
 Neuropathy 
• Macroangiopathy 
 Ischemic heart disease 
 Cerebrovascular disease 
 Peripheral artery disease 
• Neuropathy 
 Peripheral polyneuropathy 
 Autonomic neuropathy 
 Mono- or multifocal neuropathy 
 Compression neuropathy 
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Hyperglycemia induced oxidative stress in the endothelium is thought to be one of the 
main components, driving the development of these complications [48]. 
1.1.5 Burden of the disease 
422 million people in the world were calculated to have diabetes in 2014 according to WHO 
[49]. The prevalence has doubled in the adult population since 1980, from 4,7% to 8,5% in 
2014. It is difficult to assess the proportion of type 1 and type 2 diabetes in many 
international registries but the overall increase is founded on an increased prevalence of risk 
factors for T2D, such as overweight and physical inactivity. In recent years, the increase in 
diabetes prevalence has been greater in low and middle-income countries compared to high-
income countries. In Sweden, the total prevalence of diabetes in 2012 was 4.7%, according to 
a recent nation-wide register-based study. During the years 2005 to 2013, a modest increase 
in prevalence and a simultaneous decrease in incidence was demonstrated [50]. 
The impact of T2D on morbidity and mortality is huge. The risk of different vascular 
diseases, including coronary heart disease, ischemic and hemorrhagic stroke and vascular 
death, is approximately doubled in diabetes patients [51]. These increased hazards are 
independent of other cardiovascular risk factors. In patients reaching end-stage renal disease, 
diabetes is regarded the primary cause in 12 to 66% in world-wide comparisons [52]. 
Proliferative diabetic retinopathy (DR), which is potentially vision-threatening, is prevalent in 
7% of diabetes patients [53]. Further, rates of lower extremity amputations are 10-20 fold 
higher in populations with diabetes, in contrast to populations without [54]. Promisingly, the 
frequency of these complications are declining in several instances [49]. On the other hand, a 
recent meta-analysis showed that blindness and visual impairment due to DR had risen. In 
2010, DR accounted for 2.6% of all blindness and 1.9% of all visual impairment worldwide 
[55]. 
1.1.6 Treatment 
1.1.6.1 Target levels 
The aim of the treatment in T2D is to lower, or if possible normalize, glucose levels. But the 
target level of HbA1c should be individualized, taking into account risk of hypoglycemia, 
disease duration, life expectancy, comorbidities, patient attitudes and resources etc. [56].  
Moreover, other risk factors of CVD as obesity, physical inactivity, hypertension and 
dyslipidemia should be addressed. The target levels for these components have changed over 
time and are under constant evaluation and debate. The following treatment target levels have 
been proposed in Swedish National Guidelines from the National Board of Health and 
Welfare (Socialstyrelsen) and the American Diabetes Association in 2015 [57, 58] (Table 1). 
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 Socialstyrelsen 2015 ADA 2015 
HbA1c < 52 mmol/mol < 53 mmol/mol  
Blood pressure < 140/85  < 140/90 
LDL-cholesterol Not used as target, treatment 
according to estimated total CVD 
risk 
Not used as target, treatment 
according to estimated total CVD 
risk 
Urine 
albumin/creatinine 
ratio 
No recommendation < 3.4 mg/mmol  
 
Other Smoke stop Exercise > 150 min/week 
Table 1. Treatment targets in diabetes proposed by the Swedish National Board of Health 
and Welfare (Socialstyrelsen) and the American Diabetes Association (ADA). Both 
organizations emphasize individualization of the target levels. LDL: low-density lipoprotein. 
1.1.6.2 Lifestyle 
Targeting lifestyle factors, such as improved diet and increased physical activity is the 
foundation of the treatment in T2D and is advocated in guidelines [59]. A Cochrane meta-
analysis found that exercise alone lowered HbA1c by about 7 mmol/mol. Positive effects on 
visceral adipose tissue and triglycerides in blood were also detected [60]. Studies on diets are 
difficult to interpret due to the vast number of different diets used. For weight-loss, diets of 
low-carbohydrate, low-fat and calorie-restricted, as well as Mediterranean diets have proved 
efficacy up to two years [59].  
More appropriate in a clinical perspective could be to evaluate the effects of combined 
lifestyle modification, including diet, physical activity and education. A meta-analysis on this 
subject, including16 studies, demonstrated significant benefits on HbA1c, body mass index 
(BMI) and blood pressure, but not on cholesterol levels [61]. 
In prevention, lifestyle intervention with diet and physical exercise has been shown to 
decrease the risk of progression from IGT to manifest diabetes [62, 63]. In two later studies, 
the relative progression rate could be reduced by 58% [64, 65], which has been evaluated as 
highly cost-effective in a society perspective [66]. Notably, the preventive effect was lower 
(28%) in an Indian study [67]. Moreover, it could be discussed if this reflects a true 
preventive effect or if the disease is masked due to an effective lifestyle treatment.  
In the Look AHEAD trial, a great effort was made to evaluate if lifestyle modification could 
have an impact on cardiovascular morbidity and mortality in T2D. More than 5000 T2D 
subjects were randomized to intensive lifestyle modification, with the goal of a weight 
  15 
reduction of > 7% and increased physical activity, or to a control group receiving basic 
lifestyle education. However, the study was terminated in advance after a mean follow-up of 
9.6 years, since the probability of a significant group difference within the planned study-
length of 13.5 years was less than 1% [68]. This was in spite of that the intensive lifestyle-
modification group had a greater weight loss, fitness increase and a higher rate of remission 
of their diabetes than the control group after 4 years [69]. The study results were greatly 
discussed, especially concerning if the study was under-powered, since the reduction in 
weight and waist was moderate (6 % and 2 cm, respectively), and the fact that more intensive 
pharmacological treatment became clinical routine during the study period. 
1.1.6.3 Pharmacological 
1.1.6.3.1 Oral anti-diabetic agents (OADs) 
Metformin is recommended in most guidelines as the first-line pharmacological treatment in 
T2D [56]. This is chiefly founded on the cardiovascular protective effect seen in a sub-group 
in the United Kingdom Prospective Diabetes Study (UKPDS) [70] Metformin has also been 
shown to decrease the relative risk of developing T2D in IGT subjects by 26-31% [65, 67]. 
Interestingly, one of the mechanisms by which metformin have its effects is by stimulating 
AMP-kinase [71]. 
Other OADs include sulfonylureas, glinides, acarbose, thiazolidinediones, dipeptidyl 
peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors. 
Special interest has lately been shown in the SGLT2 inhibitors, since one compound, 
empagliflozin, recently showed a pronounced cardio-protective effect [72]. 
1.1.6.3.1.1 ACARBOSE 
Acarbose is an α-glucosidase inhibitor that decreases post-prandial hyperglycemia by 
delaying carbohydrate absorption from the small intestine [73]. It lowers HbA1c in mean by 
9 mmol/l according to a Cochrane meta-analysis, without significant impact on body weight 
or serum lipids [74].  
Further, in a meta-analysis of trials on acarbose treatment in T2D, acarbose was associated 
with a 35% reduction of CVD [75]. The evaluated outcomes were collected from adverse 
events registered in each study, and thus the studies included were in fact not designed for 
evaluation of cardiovascular (CV) events. Notably, acarbose treatment significantly 
improved several CV risk factors such as glycemic control, triglyceride levels, BMI and 
blood pressure. In a secondary analysis of the STOP-NIDDM trial, acarbose treatment was 
associated with a significant absolute risk reduction in cardiovascular events by 2.5% in a 
IGT population [76]. The trial was criticized for using a “modified” intention-to-treat group 
for the analysis, excluding subjects who discontinued very early [77, 78]. It has been 
proposed that the mechanism behind the benefits of acarbose on CV risks could be lowering 
of oxidative stress, secondary to the decrease of postprandial glucose by the compound [79]. 
Moreover, acarbose was also shown to decrease the progression from IGT to T2D in the 
STOP-NIDDM study [80]. However, the effect was smaller than in lifestyle intervention 
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trials. Further, when all study subjects were put on placebo at the end of the study and re-
examined three months later, the progression to diabetes was rather high in the formerly 
acarbose-treated group. 
1.1.6.3.2 Insulin 
Insulin has long been an effective treatment option in T2D. Insulin is often necessary in long-
standing disease when β-cell function has declined considerably. Different insulin 
formulations and adjustments to the insulin molecule have provided several variants for 
treatment with either short or long-acting properties. 
1.1.6.3.3 Glucagon-like petide-1 (GLP-1) analogues 
A fairly new treatment option is founded on the incretin hormone GLP-1. As opposed to the 
DPP-4 inhibitors, that achieve an increase in endogenous produced GLP-1, these agents 
create higher plasma levels by exogenous administration of modified variants of the 
hormone. They are at present made for subcutaneous injection only. Interestingly, some of 
these compounds have been attributed substantial cardio-protective effects in recent trials [81, 
82]. 
1.1.6.4 Multifactorial treatment 
Given the high frequency of several CV factors in T2D, the importance of multifactorial 
treatment is recommended by most organizations. The impact of such a strategy has been 
evaluated, establishing a great advantage in risk reduction in diabetes-related complications. 
In the Steno-2 trial, T2D subjects with microalbuminuria were intensively treated for tight 
glucose regulation, as well as optimal control of other CV risk factors. Compared to 
conventional treatment, the intensive multifactorial approach for 7.8 years significantly 
decreased the risk of cardiovascular disease (hazard ratio 0.47) and microvascular outcomes 
[83]. Observational data for an additional 13 years showed sustained benefits, as well as 
lower rates of total and cardiovascular mortality. A gain of nearly eight years in lifespan 
could be demonstrated [84]. 
1.2 PHYSICAL EXERCISE IN TYPE 2 DIABETES AND AT-RISK 
POPULATIONS 
As mentioned before, physical activity has long been emphasized as part of the lifestyle 
treatment in T2D, and also as an element in preventing the disease in high risk subjects. 
1.2.1 Effect on hyperglycemia and other cardiovascular risk factors 
An early meta-analysis on the effect of exercise in T2D subjects revealed an average decrease 
in HbA1c of 7 mmol/mol, despite of the absence of weight loss [85]. In the two included 
studies also using diet co-intervention, the effect on HbA1c was more pronounced. A similar 
effect was seen in the Cochrane review mentioned previously [60]. The effect of exercise on 
insulin resistance is often pronounced [86]. There is some evidence that exercise may 
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improve β-cell function, when measured as disposition index during an intravenous glucose 
tolerance test [87]. 
Moreover, significant effects on abdominal (or visceral) obesity, serum triglycerides and 
blood pressure are often accomplished in exercise studies [60, 88]. 
1.2.1.1 Mode of exercise 
No association between exercise intensity or volume and effect on HbA1c could be 
confirmed in two different reviews [85, 89]. However, later Boulé et al. did found evidence 
that exercise intensity was more important than exercise volume in improving VO2max and 
HbA1c [90]. The highly intensive exercise in fairly young T2D subjects (mean age 45 years) 
at 75% of VO2 peak, two sessions/week, and interval exercise one session/week in the study 
of Mourier et al. decreased HbA1c from 8.5 to 6.2% and increased VO2 peak by 41% [91]. 
However, intense exercise might be hazardous and screening for CVD has been 
recommended in high risk individuals [92]. 
The most common exercise modalities studied in T2D and other populations are aerobic 
exercise, resistance training or the combination of both. In a meta-analysis, aerobic exercise 
alone, or in combination with resistance training, appeared more effective than resistance 
training alone. These modalities improved glycemic control, systolic blood pressure and 
triglycerides. Waist circumference was reduced by resistance training or the combined 
exercise [88]. The combined mode of exercise was also more effective in improving insulin 
sensitivity in sedentary adults [86]. 
1.2.1.2 Differences in response 
The individual response to exercise training shows a large variation when measured as insulin 
sensitivity in a healthy sedentary population. In addition, men seem to respond better [93]. 
The response in respect of VO2max also displays a wide variation [94]. Moreover, changes in 
gene expression are associated with the individual response to the exercise [95, 96]. It has 
been postulated that this individual response should be considered in studies evaluating 
effects on gene expression by physical exercise [94]. 
Moreover, there are studies showing that subjects with, or at-risk of, T2D respond less to 
exercise intervention than healthy individuals. Thus, first-degree relatives to subjects with 
T2D did not respond as well as those without heredity to a seven months’ exercise program, 
when measured as VO2max, weight and waist circumference, taking exercise volume into 
account [97]. This was associated to a lesser increase in expression of genes involved in 
oxidative phosphorylation and metabolism, compared to those without heredity [97]. 
1.2.2 Effects on cardiovascular outcomes 
Observational data supports that an active lifestyle decreases the risk of adverse CV events 
and mortality in T2D [46, 98, 99]. A high level of physical activity at baseline, assessed by 
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pedometer, was associated with a less increase in measure of arterial stiffness after four years 
[100]. 
On the other hand, when subjects were randomized to intensive lifestyle modification in the 
Look AHEAD study, no impact was seen on hard end-points as CV morbidity or mortality 
[68]. 
1.2.3 Mechanisms 
The mechanisms behind the positive impact of exercise on hyperglycemia and other 
cardiovascular risk factors are complex and not fully understood. Exercise training affects the 
expression of more than 500 genes [95]. Since most of the glucose uptake in the human body 
occurs in skeletal muscle, research has focused on understanding the mechanisms in this 
tissue.  
Acute exercise induces translocation of GLUT4 through an insulin-independent mechanism. 
This was demonstrated in mice with a muscle-specific knock-out of the insulin receptor. 
These mice had a normal exercise-induced glucose uptake in muscle despite no 
responsiveness to insulin [101]. The GLUT4 translocation is probably mediated through 
several mechanisms. AMP-kinase [102] and Ca2+/calmodulin-dependent protein kinases are 
of importance, as well as more downstream targets, such as AS160 and TBC1D1, that are 
shared with insulin signaling pathways [103]. 
In chronic exercise training, blood flow/angiogenesis as well as mitochondrial activity will be 
of importance. This will be discussed in the sections below. 
1.2.3.1 Angiogenesis 
Activation of angiogenesis in response to exercise training is probably of great importance for 
the different effects seen in metabolism. Early studies demonstrated that endurance training 
increases capillary density, or capillaries per fibre ratio, in human skeletal muscle [104]. This 
would in turn improve exchange of gas and substrate by increased surface area and blood 
residence time, as well as decreased diffusion distance. The favorable result of this could be 
increased glucose uptake, lipoprotein metabolism, insulin sensitivity and enhanced glucose 
tolerance [105]. 
1.2.3.1.1 Vascular endothelial growth factor (VEGF) 
VEGF and its receptors are major angiogenetic factors [106]. There are several different 
isoforms of VEGF, where isoform A (VEGF-A) is the most relevant [107]. Henceforth, 
VEGF will be equivalent to VEGF-A in this text. VEGF exerts its effects by binding to the 
receptors VEGFR-1 and VEGFR-2 that are mainly expressed in endothelial cells [108]. 
Expression of the VEGF gene is greatly stimulated by exercise [109], especially in untrained 
muscle [110]. Blockade of the VEGF receptors reduce capillary density in rats [111]. 
Further evidence of the importance of VEGF was seen in a muscle-specific VEGF knock-
out mouse-model that resulted in a 60% decrease in capillary density, accompanied by a 
56% reduction in insulin stimulated glucose uptake [112]. 
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1.2.3.1.2 Angiopoietin 
The angiopoietin pathway has also been shown to be of importance, in association with 
VEGF, in the exercise-induced angiogenic response of skeletal muscle in rat [113] and in 
humans [114]. In humans, the angiopoietin related genes were especially activated in those 
who improved their VO2max the most [94]. 
1.2.3.1.3 Other factors 
Some other important factors and stimuli in exercise-induced angiogenesis include nitric 
oxide (NO), mechanical stress and perhaps hypoxia [105, 114]. Remodeling of the 
extracellular matrix, by in particular matrix metalloproteinases, is probably of importance 
as well [115]. 
1.2.3.2 Mitochondrial function and PGC-1α 
Genes involved in oxidative phosphorylation and peroxisome proliferator-activated receptor-
gamma coactivator 1α (PGC-1α) are downregulated in muscle of diabetic subjects [116], and 
likewise in those with heredity for T2D [23]. PGC-1α was first described as an important 
factor in mitochondrial thermogenesis [117]. Further studies proved PGC-1α to be involved 
in energy metabolism and muscle adaptation to exercise [118]. Exercise activates the AMP-
kinase pathway, which in turn probably regulate and activate PGC-1α [119].  More recently, 
PGC-1α has also been shown to regulate angiogenesis and VEGF expression, in response to 
hypoxia and nutrient deprivation, in animal muscle [120]. This was also demonstrated in 
exercise-induced angiogenesis, where the effects of PGC-1α on VEGF expression were 
mediated through the estrogen-related receptor alpha [121, 122]. 
1.3 ENDOTHELIN-1 IN TYPE 2 DIABETES 
The endothelin-1 (ET-1) system seems to be activated in conditions such as obesity, T2D and 
metabolic syndrome. This activation has a negative effect on endothelial function and insulin-
induced vasodilatation, which seems to be normalized by blockade of ET receptors. Drugs 
targeting the ET-1 pathways could be interesting to prevent vascular complications in 
obesity-linked disorders [123]. 
1.3.1 Basic physiology 
ET-1 is a potent vasoconstrictor peptide, first isolated from porcine aorta. ET is first released 
as the propeptide Big ET (1-38 amino acids), which is then cleaved into ET (1-21) and a C-
terminal fragment (22-38) [124]. ET is present in three different isoforms, where ET-1  is 
considered the most important in regard to cardiovascular effects [125]. It is mainly produced 
by endothelial cells, but can be produced by several other cell types in pathophysiological 
conditions. It is considered as an important factor in the evolution of vascular dysfunction and 
CVD [126]. 
ET-1 exerts its effects via two different receptors, endothelin receptor A (ETA) and B (ETB) 
[125]. ETA is predominantly present on vascular smooth muscle cells, where its activation 
induces vasoconstriction. In contrast, ETB is mainly located on endothelial cells, but can also 
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be expressed on vascular smooth muscle cells. It mediates vasodilatation through release of 
NO and prostacyclin [127]. Hence, the effect of ET-1 will be a result of the balance between 
these two receptors. Normally, the net effect will be vasoconstriction by the ETA receptor, 
that in part will be balanced by the vasodilatory effect of ETB [126]. 
1.3.2 Endothelin-1 and insulin resistance 
Research has suggested that ET-1 could be an important factor in insulin resistance. 
Circulating ET-1 levels are increased in subjects with insulin resistance and hyperglycemia 
[128]. Further, basal ET-1 levels were negatively correlated to total glucose uptake in a clamp 
study on men with T2D [129]. 
In rats, administration of ET-1 for 5 days led to a 30% reduction in total insulin-stimulated 
glucose disposal [130]. Likewise, ET-1 infusion in humans decreased insulin sensitivity by 
approximately 30%, without influencing blood flow in skeletal muscle [131]. Infusion of the 
precursor Big ET-1 also reduced insulin sensitivity in healthy humans [132]. 
1.3.3 Endothelin-1 and endothelial dysfunction 
Endothelial dysfunction could be described as an imbalance between vasodilatory factors, 
where NO is most important, and vasoconstrictive factors, such as ET-1 [133], as well as pro-
atherogenic oxygen-derived free radicals [134]. It is hypothesized that endothelial 
dysfunction is an early defect in the arteriosclerosis process. Endothelial dysfunction has been 
detected in subjects with T2D or insulin resistance, and also in those at risk of developing 
T2D [135]. 
Several mechanisms by which insulin resistance could be connected to endothelial 
dysfunction have been proposed, including influence on NO production, oxidant stress, ET, 
the renin-angiotensin system, as well as cytokines produced in adipose tissue [136]. 
1.3.4 Endothelin-1 receptor blockade 
Blockade of the endothelin-1 receptors has been used to study the impact of the ET-1 system. 
Endothelium-dependent vasodilatation improved with ETA receptor blockade in patients with 
atherosclerosis [137]. In obese individuals, selective ETA receptor blockade enhanced insulin-
stimulated glucose uptake, by increasing both blood flow and glucose extraction in the leg. 
Lean subjects did not show these effects [138]. Further, ETA receptor blockade augmented 
blood flow in the forearm in T2D subjects more than in controls. Dual ETA/ETB blockade did 
not further increase this response [139]. Consequently, the ET-1 system seems to be of more 
importance for vasoconstriction in T2D than in non-diabetic subjects.  
Dual ETA/ETB receptor blockade might be of greater advantage than selective blockade of the 
ETA receptor. In subjects with insulin resistance, dual blockade increased endothelium-
dependent vasodilatation. That was in contrast to selective ETA receptor blockade, that had no 
effect compared to placebo [140]. Moreover, dual blockade acutely increased insulin 
sensitivity, measured by hyperinsulinemic clamp, in insulin resistant subjects. Conversely, 
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ETA blockade did not show any effect [141]. But some studies have not proven dual blockade 
to be superior. As mentioned above, dual blockade in the study by Cardillo et al. did not 
augment the response on blood flow more than ETA-blockade alone in T2D subjects [139]. 
A clinical placebo-controlled trial evaluating dual endothelin blockade (bosentan) have 
shown improved peripheral endothelial function in patients with long-standing T2D and 
microalbuminuria. No effects on glycemic indices were seen, but most of the subjects had 
more advanced treatment including insulin [142]. 
1.3.5 The complex interplay between insulin and endothelin-1 
In the endothelium, insulin stimulates NO production by activation of the PI3-kinase 
dependent pathways, and thereby promoting vasodilatation. But ET-1 production, with its 
mainly vasoconstrictive effect, is also stimulated by insulin [143], but via the MAP-kinase 
dependent pathways [144]. Consequently, ET-1 levels in blood increased during 
hyperinsulinemic clamp in T2D individuals [129]. 
Interestingly, ET-1 can influence the insulin pathways. In arterial smooth muscle cells, ET-1 
diminished PI3-kinase activity, suggesting interference with insulin signaling [145]. In 
adipocytes pre-treated with ET-1, insulin signaling through both the PI3-kinase and MAP-
kinase pathways were impaired [146]. In later in vitro studies, the insulin resistance evoked 
by ET-1 seemed to involve the phosphatidylinositol 4,5-bisphosphate (PIP2)/actin system 
[147], which impaired GLUT4 translocation [148]. 
Insulin and ET-1 counteract each other in the vasoconstrictor system. In perfused hindlimb of 
rat, insulin blocked the vascular effects of ET-1 by its vasodilatory effect [149]. Moreover, in 
arteries from insulin-resistant rats, ETA blockade normalized the vasodilatory response to 
insulin [150]. This suggest an increased activity of ET-1 in insulin resistance. 
1.4 VITAMIN D IN TYPE 2 DIABETES 
The inference of an impact of vitamin D status on T2D and related conditions emanates 
mainly from observational data. In cross-sectional observational studies, there is a fairly 
consistent association between low 25-hydroxy-vitamin D3 (25(OH)D) levels and prevalence 
of T2D or the metabolic syndrome [151]. 
1.4.1 Basic vitamin D physiology 
Classical effects of vitamin D includes regulation of calcium and phosphate homeostasis, as 
well as bone mineralization. Its active form 1,25-dihydroxy-vitamin D3 (1,25(OH)2D) binds 
to the nuclear vitamin D receptor and exerts its effects by influencing gene expression. 
Sources of vitamin D are conversion in the skin of 7-dehydrocholesterol in two steps to 
vitamin D3 by UV-light, or by foods containing or fortified with vitamin D2 or D3. Vitamin 
D3 are subsequently 25-hydroxylated, primarily in the liver [152]. The serum levels of the 
product 25(OH)D are proportional to vitamin D intake, and has therefore long been regarded 
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as a good proxy of vitamin D status [153]. But there has been some doubt raised lately about 
the accuracy of that assumption [154]. The optimal serum concentration of 25(OH)D for 
different health outcomes has been much debated. Some authors have advocated higher 
levels, often above 75 nmol/l [155, 156], whereas Institute of Medicine (IOM) has advocated 
a more conservative approach [154].  
The second step in the activation of vitamin D3 is performed by 1α-hydroxylase, mainly in 
the kidney. This creates the active metabolite 1,25(OH)2D. The main catabolic step in 
deactivation of this compound creates 24,25-dihydroxy-vitamin D3, which then is further 
degraded [152]. 
The classic target organs for 1,25(OH)2D include the intestine, where calcium and phosphate 
absorption are enhanced. Further, vitamin D is important in the mineralization process of the 
skeleton, although probably not vital [157]. Finally, 1,25(OH)2D suppresses the production of 
parathyroid hormone (PTH), whereas PTH stimulates 1α-hydroxylase in the kidney and thus 
increases formation of 1,25(OH)2D [152]. 
1.4.2 New perspectives 
Aside from the classical related disease rickets, vitamin D deficiency has lately been related 
to several other health issues. These include neuromuscular function and risk of falls, dental 
health and various cancers. Further, immune-related disorders as type 1 diabetes, multiple 
sclerosis, rheumatoid diseases, psoriasis and inflammatory bowel disease have been 
considered, as well as hypertension and T2D  [155, 158]. But evidence of a clear role of 
vitamin D supplementation in these pathologic states are in most cases lacking [159]. Even in 
osteoporosis, the support for vitamin D treatment alone has little support according to a recent 
meta-analysis [160]. 
One of the basis of the interest in vitamin D originates from the fact that the receptor for the 
active metabolite 1,25(OH)2D is present in more than 30 tissues [161], including pancreatic 
β-cells [162]. Moreover, the enzymatic conversion of 25(OH)D to 1,25(OH)2D is possible in 
several locations, including the pancreatic β-cells [163]. Theoretically, the active 1,25(OH)2D 
metabolite could thus be produced locally within the pancreatic islet and exert autocrine 
effects. 
Another interesting aspect is that higher PTH levels have been associated to CVD. In the 
ULSAM cohort, PTH levels were positively associated to CV mortality in men [164]. An 
interaction with vitamin D status could be of importance for this finding. Notably, in a recent 
study evaluating metabolic effects after surgery for primary hyperparathyroidism, IR 
resistance measured by HOMA index was reduced six weeks postoperatively. Importantly, 
randomization to vitamin D treatment after surgery for one year did not influence IR or other 
CV risk factors in comparison to placebo, despite a higher 25(OH)D level and a lower PTH 
level in the vitamin D treated group [165]. 
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1.4.3 Observational studies 
Aside from the cross-sectional data of associations between 25(OH)D levels and T2D 
prevalence mentioned above [151], there are also prospective studies on the subject. In the 
large prospective Nurses´ Health Study cohort study, the risk of developing T2D was lower 
in subjects with a high intake of vitamin D or calcium, compared to those with a low intake 
[166]. A significant 40% reduction in relative risk of acquiring T2D were seen in a Finnish 
prospective cohort study, evaluating the impact of the highest and lowest quartiles of baseline 
25(OH)D values. This finding suggested a protective effect of a high 25(OH)D level. 
Notably, the risk dropped to a trend when adjusting for multiple other risk factors for T2D 
[167]. However, in the Ely prospective study, levels of glucose tolerance, fasting insulin, 
insulin resistance (homeostasis model of assessment, i.e. HOMA index) and metabolic 
syndrome risk score were significantly lower in those with a high baseline 25(OH)D, even 
after adjustment for competing risk factors related to T2D [168]. In the Stockholm Diabetes 
Prevention Study (SDPP), high baseline 25(OH)D levels in men were protective in respect to 
development of T2D after 8-10 years. This relationship was seen in men with IGT, but not in 
those with normal glucose tolerance at baseline or in women [169]. A meta-analysis of 21 
prospective studies confirmed the association, showing a significant hazard ratio of 0.62 
when comparing risk of incident diabetes for those with high 25(OH)D levels compared to 
those with low levels at baseline. Adjustment for BMI and other related factors diminished 
the association slightly, but it remained significant [170]. 
1.4.4 Randomized intervention studies 
Previous randomized studies are scarce. Randomization to 1000 mg of calcium and 400 IU 
vitamin D3 supplement per day in post-menopausal women was not associated with a 
decreased risk of incident T2D during 7 years of follow-up [171].  
1.4.5 Mechanistic studies 
1.4.5.1 Β-cell function 
In vitro as well as in vivo animal studies in the 80´s suggested that vitamin D could have an 
impact on insulin release [172, 173]. This evoked several trials in human subjects. A vitamin 
D3 dose of 2000 IU per day to subjects with vitamin D deficiency increased insulin secretion 
after an OGTT [174]. In vitamin D deficient Asians living in London and having slightly 
elevated glucose levels, a single dose of 100 000 IU vitamin D3 augmented insulin and C-
peptide response to an OGTT after 2-3 months. Notably, glucose tolerance was unchanged 
[175]. First-phase insulin secretion during an intravenous glucose tolerance test (IVGTT) 
increased significantly in females with T2D after one month of treatment with vitamin D3 
1332 IU per day [176]. Further, 3 weeks of treatment with 2 µg of active vitamin D (1α-
(OH)D3) increased total insulin response after an OGTT in T2D subjects [177]. A slight but 
significant increase in first-phase C-peptide levels after IVGTT were also seen in healthy 
subjects, taking 3 µg of active vitamin D (1,25(OH)2D) for four days [178]. 
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In contrast, four days of treatment with one µg of active vitamin D3 to T2D subjects did not 
augment insulin response to a meal test [179]. In addition, 40 000 IU of vitamin D3 once 
weekly for six months did not improve insulin secretion, calculated with HOMA index in 
T2D subjects [180]. In centrally obese men living in India, a high-dose treatment of three 
injections of 120.000 IU vitamin D3, separated by 14 days, did not improve insulin secretion 
assessed by HOMA index [181]. 
1.4.5.2 Insulin sensitivity 
There are a few reports of increased insulin sensitivity by vitamin D treatment. In the Indian 
study by Nagpal et al. mentioned above, insulin sensitivity measured by the OGTT-based 3-
hour oral glucose insulin sensitivity (OGIS) index was significantly improved. Noteworthy, 
other indices of insulin sensitivity (HOMA, quantitative insulin sensitivity check index 
[QUICKI]) were not affected [181]. In a post-hoc analysis of a study focusing on bone-
related outcomes, combined treatment with calcium and 700 IU vitamin D3 slowed 
progression of insulin resistance over three years in those with IFG at baseline [182].  
Conversely, most studies have not been able to detect this association. For example, the 
intravenous glucose tolerance test (IVGTT) based study by Borissova et al. and the six-month 
long study by Jorde et al. were neutral in this respect [176, 180]. In a subset of participants in 
the Women’s Health Initiative study, HOMA index of insulin resistance did not differ 
between those allocated to calcium + vitamin D or placebo [171]. Several indices of insulin 
sensitivity, including the OGTT-based Insulin Sensitivity Index (ISI), were unaltered after 
two injections of 100 000 IU vitamin D3 given to adults with vitamin D deficiency [183]. 
Moreover, one study using the euglycemic clamp could not find any benefit of active vitamin 
D treatment with two µg of α-25(OH)D per day in men with IGT. However, no control group 
was used [184]. Finally, 1.5 µg of active 1,25(OH)2D for seven days did not affect the M-
value, obtained by euglycemic clamp, in comparison with placebo in healthy males [185]. 
A cross-sectional study on overweight post-menopausal women gave support of a threshold 
effect of 25(OH)D level on glucose tolerance, fasting insulin and insulin resistance (HOMA 
index). The threshold level for the associations was set to 65 nmol/l [186].  
1.5 MISSING INFORMATION 
Physical exercise has been shown to positively affect several of the included risk factors but 
the additive effects of OADs to physical training is unknown. 
Further, the response to physical exercise demonstrates a large individual variation. VEGF is 
a key player in angiogenesis and PGC-1α is a crucial factor in mitochondrial function. If 
these components thereby could promote improved insulin sensitivity by exercise, to a 
diverse extent in separate individuals, has not been studied. 
ET-1 is another factor that could be important in glucose metabolism and insulin sensitivity. 
Blockade of the ET-1 receptors A and B (dual blockade) has been shown to increase glucose 
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uptake and insulin sensitivity in insulin resistant subjects, but it is unclear how ET-1 more 
precisely interferes with glucose metabolism. 
Vitamin D could, according to epidemiological studies, have an important role in glucose 
homeostasis, and thereby be a putative agent for prevention of T2D in subjects with 
prediabetes or treatment of T2D. However, mechanistic studies in humans have yielded 
conflicting results as if vitamin D has effects on β-cell function and insulin sensitivity. 
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2 AIMS 
To study, in patients with T2D and mild hyperglycemia, the effect of structured exercise 
training alone and in combination with acarbose treatment on glycemic control, body 
composition, and cardiovascular risk factor profile. 
To investigate if associations exist between changes in expression of key genes and improved 
insulin sensitivity, VO2max and glycemic control following exercise training in T2D, in the 
context of individual physiological adaptation. 
To test the hypothesis that endogenous ET-1 contributes to impaired skeletal muscle glucose 
uptake in insulin-resistant subjects in vivo. Furthermore, to elucidate the direct actions of ET-
1 on glucose metabolism and insulin signaling in skeletal muscle in vitro. 
To investigate the effect of high-dose vitamin D treatment in people with prediabetes or drug-
naïve T2D on β-cell function, insulin sensitivity, and glucose tolerance.
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3 METHODOLOGICAL CONSIDERATIONS 
3.1 STUDY SUBJECTS 
3.1.1 Study I and II 
We recruited study subjects from referrals to our outpatient diabetes daycare unit at 
Karolinska University Hospital, and by advertising in newspapers. Inclusion criteria included 
T2D diagnosis since at least 3 months, HbA1c <68 mmol/mol, age 45-60 years and BMI 25-
30 kg/m2. Permitted diabetes treatments were diet and no more than one oral antidiabetic drug 
(OAD). None of the study subjects took part in any regular exercise program with more than 
one training session per week. 
3.1.2 Study III 
3.1.2.1 In vivo study 
We recruited sedentary males with IR, assessed by euglycemic-hyperinsulinemic clamp or 
HOMA index. Cut-off levels to categorize subjects as insulin resistant are arbitrary, but we 
used cut-off limits that have been recommended [187]. 
3.1.2.2 In vitro study 
Muscle samples from m. rectus abdominis were collected from eight individuals during 
elective abdominal surgery. These subjects had no metabolic disorders. 
3.1.3 Study IV 
We recruited participants from the Stockholm Diabetes Prevention Program (SDPP), a 
prospective cohort study in Stockholm [188]. Subjects in SDPP were enrolled from five 
municipalities in Stockholm county during the period 1992 to 1998. A questionnaire was sent 
to all inhabitants aged 35-55, asking about present diabetes diagnosis and family history of 
diabetes (FHD). In the second step, subjects without diabetes but with FHD, together with 
randomly age- and sex-matched controls without FHD, were invited for an examination. This 
examination consisted of blood sampling, an OGTT, body measurements and a questionnaire 
about lifestyle. A baseline group of almost 8000 individuals was collected and re-invited 8-10 
years later for a follow-up investigation, excluding those who were diagnosed with diabetes 
at baseline. Over 5500 subjects were re-examined by the same procedure as the baseline 
investigation. For the present study, we contacted by phone those who at follow-up in the 
years 2003–2006 were categorized as having prediabetes (IFG, IGT or both). Those who had 
the potential to meet eligibility criteria were invited to a screening visit.  
Major inclusion criteria included: 1) IFG, IGT, IFG + IGT, or drug-naïve diabetes at the 
screening OGTT; 2) age 45 to 75 years, female or male; 3) BMI ≤32 kg/m2; 4) HbA1c ≤63 
mmol/mol); 5) fasting plasma glucose <9mmol/l and 6) serum 25(OH)D <75 nmol/l (below 
normal lab reference). 
  28 
3.2 STUDY DESIGNS 
3.2.1 Study I and II 
After a wash-out period for 6 weeks of any OAD, the subjects were randomized to one of 
three interventions for a period of twelve weeks: 
1. Aerobic/anaerobic exercise group training, for 50 minutes three times weekly. 
2. Exercise (as in intervention 1) and acarbose treatment (as in intervention 3). 
3. Acarbose treatment alone. The target dose was 100mg three times daily in 
conjunction with major meals. The dose was up-titrated during the first four weeks. 
Acceptable compliance according to pill-count was set to 75-120%. 
Further, the study design included that 10 individuals within each intervention group were 
randomized to undergo muscle biopsies for gene expression analyses (study II). All 
assessments, including muscle biopsies, were performed before and after the twelve-week 
intervention period (Figure 1). 
Included subjects were instructed to maintain their diet and exercise habits during the study 
period, except that of the allocated intervention. 
 
Figure 1. Study design and major assessments in study I and II. CT; computerized 
tomography, DXA; dual-energy X-ray absorptiometry. 
3.2.2 Study III 
Three different protocols were applied in the in vivo study on each study subject (see Figure 
2). NaCl was given during minute -30 to minute 0 in all protocols. NaCl was also infused 
when necessary to balance the rate of infused volume in all three protocols. 
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• Protocol A: Infusion of BQ123 (ETA blockade) and BQ788 (ETB blockade) were 
given for 120 minutes. Insulin was infused from minute 60 to minute 120. 
• Protocol B: Insulin was infused for 120 minutes. 
• Protocol C: Insulin was infused for 135 minutes. ET-1 was infused from minute 60 to 
minute 135. 
The investigations were separated by at least one week and were performed in random order, 
blinded to the subjects. To investigate possible time-dependent differences in protocol C, 
seven subjects were given a 15-minute prolonged ET-1 infusion.  
 
Figure 2. The three different protocols (A-C) in study III. Reprinted with the 
kind permission of A. Shemyakin. 
In the in vitro study, muscle biopsies from m. rectus abdominis were taken during planned 
abdominal surgery. 
3.2.3 Study IV 
This study was a randomized 1:1, parallel-group, double-blind, placebo-controlled study with 
an 8-week intervention period. Study centers at Karolinska University hospital and 
Södersjukhuset in Stockholm were used.  
Primary outcome was the relative change in first-phase serum insulin secretion (0–12 min) 
during the hyperglycemic clamp investigation at study end, compared with baseline, between 
the two groups. Secondary end-points comprised relative change in second-phase insulin 
secretion (12–120 min), insulin sensitivity, and disposition index (DI) during the 
hyperglycemic clamp. Furthermore, secondary outcomes were change in glucose tolerance, 
change in fasting plasma glucose and HbA1c, and change in blood lipids between the two 
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groups. Moreover, change in 25(OH)D serum levels and safety end-points such as incidence 
of hypercalcemia and adverse events were assessed. Study design and major assessments are 
seen in Figure 3. 
 
Figur 3. Study design and major assessments in study IV. OGTT; oral glucose tolerance test. 
3.3 INTERVENTIONS 
3.3.1 Exercise training (study I and II) 
A combined aerobic and resistance group training was used. This exercise modality has been 
shown to probably be more effective than aerobic or resistance training alone [86, 88] on 
metabolic outcomes. Moreover, a group training concept of this modality is widely used and 
well known in Sweden, provided for instance by the organization Friskis & Svettis©. 
Physiotherapists supervised each training session. There were two exercise targets [189]: 
1. An intensity of ≥50% of maximal exercise capacity, based on maximal heart rate 
during the exercise test at baseline, during ≥40 minutes. 
2. An intensity of ≥80% during three periods of 3-4 minutes. 
The participants were urged to reach an exertion of 13–15/20 on Borg’s Rated Perceived 
Exertion scale during the heavier parts and 9–11/20 during the rest of the program [190]. 
Further, an online heart rate recording system was used (Activio, Stockholm, Sweden) to 
ascertain that exercise intensity was reached. This was applied at one of the weekly training 
sessions during weeks 1, 6 and 12 of the training period. This design comprised adjustment of 
the workload as the subjects became trained during the twelve-week period. 
  31 
3.3.2 Acarbose treatment (study I and II) 
The target dose of acarbose (Bayer AG) was 100 mg three times daily to be taken in 
conjunction with major meals. A total of 50 mg was added every week, reaching the dose 50 
mg t.i.d. the third week. The fourth week the dose was increased to 100 mg t.i.d. If 
gastrointestinal side-effects occurred, the titration period was prolonged and/or the target dose 
reduced. 
3.3.3 Endothelin-1, endothelin receptor blockade and insulin (study III) 
ET-1 (Alexis Biochemicals, Lausen, Switzerland) was infused at the rate 20 pmol/min. 
BQ123 (ETA receptor antagonist) and BQ788 (ETB receptor antagonist) (both NeoMPS, 
Strasbourg, France) was infused at the rate 10 nmol/min. Insulin (Actrapid, 100 IU/ml; Novo 
Nordisk, Bagsværd, Denmark) was dissolved in 0.9% saline and blood immediately before 
use, and infused at the rate 0.05 mU x kg-1 x min-1. All infusions were given by the brachial 
artery. Bosentan (dual ETA/ETB receptor blockade) (courtesy of Dr. Martine Clozel, Actelion 
Pharmaceuticals, Switzerland) was dissolved in double-distilled water, stored frozen at -
80°C, and then diluted to the proper concentration in cell culture media on the day of the 
experiments. 
3.3.4 Vitamin D (study IV) 
Participants were randomly assigned to receive vitamin D3 (Vigantol Oil©), 30 000 IU (1.5 
ml/45 drops) given orally once weekly, or matching placebo oil. Merck KGaA (Darmstadt, 
Germany) manufactured vitamin D3 and matching placebo, which were both delivered in 
identical dark bottles. The first dose was given at the randomization visit after study 
assessments. The fifth dose was given at the half-time visit. The other six doses were taken 
by the subject at home and study drug bottles were brought to the study center by each 
participant for compliance assessment. 
3.4 ASSESSEMENTS 
3.4.1 Oral glucose tolerance test (study IV) 
After a fasting plasma glucose was obtained (0 minutes), 75 grams of glucose dissolved in 
water was given orally. Plasma glucose was obtained at 30 and 120 minutes after the glucose 
administration. The baseline investigation was performed at the screening visit. WHO criteria 
[10] were applied to determine glucose tolerance category according to: 
• IFG = fasting plasma glucose 6.1–6.9 mmol/l 
• IGT = 2-hour plasma glucose 7.8–11.0 mmol/l 
• Diabetes = fasting plasma glucose ≥7.0 mmol/l and/or 2-hour plasma glucose ≥11.1 
mmol/l) 
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3.4.2 Euglycemic-hyperinsulinemic clamp (study I, II and III) 
In the studies we have used the clamp technique first described by DeFronzo in 1979 [191]. It 
is still considered as the golden standard when assessing insulin sensitivity. Other, less 
resource-demanding, methods have evolved, but are still compared against the clamp method 
[192]. The principle entails to raise insulin levels and add glucose intravenously to avoid 
hypoglycemia and maintain normoglycemia. The amount of glucose infused gives an 
estimate of insulin sensitivity (M). 
The investigation was performed in the morning, after the subjects had fasted overnight. After 
the intervention period in studies I and II, the insulin clamp studies were repeated and 
performed 24–36 h after the last bout of exercise in intervention groups 1 and 2. Insulin 
(Actrapid; Novo Nordisk, Copenhagen, Denmark) was dissolved in saline and a small 
amount of the subject´s blood, to minimize insulin adherence to the infusion set. Insulin was 
infused at 1.0 mU x kg-1 x min-1 for 120 minutes. During the first 10 minutes, the insulin 
infusion rate was increased in a step-wise manner in order to faster reach steady-state 
concentrations of insulin. Glucose (200 mg/ml) was simultaneously infused intravenously at a 
variable rate to maintain the blood glucose concentration stable at 5.0 mmol/l. For this 
purpose, blood glucose was sampled every 5 to 10 minutes.  
3.4.2.1 Calculations 
Glucose infusion rate at the end of the clamp assessed insulin sensitivity (M), and was 
corrected for lean body mass as insulin-stimulated glucose uptake occurs primarily in skeletal 
muscle [22]. Insulin sensitivity index (M/I) was calculated by dividing M by the mean insulin 
levels (I) during steady state (study II). 
3.4.3 Hyperglycemic clamp (study IV) 
The hyperglycemic clamp, also described in 1979 by DeFronzo [191], is considered as the 
golden standard method when assessing β-cell function. It has also been proven to give a 
valid measurement of insulin resistance, with highly correlated R-values of approximately 
0.85 in comparison with the hyperinsulinemic-euglycemic clamp [191, 193]. 
The investigation implies increasing plasma glucose from the baseline level by a glucose 
infusion. This will stimulate the endogenous insulin secretion, which will constitute a 
measure of β-cell function. 
Glucose 200 mg/ml was infused intravenously for 120 minutes at a variable rate to increase 
plasma glucose to a target value of 6.9 mmol/l above the fasting glucose value. The first 14 
minutes, a relatively high infusion rate was administered in a stepwise manner, based on 
estimated body surface, to faster reach a steady state. For the remainder of the investigation, 
the infusion rate was based on preset computer calculations, as described previously [191]. 
Arterialized blood for sampling of glucose and insulin levels were obtained from a retrograde 
inserted venous injection needle in a heated hand. Sampling was done every 2 min from 
minute 0 to 14, and thereafter every 5-10 minutes until the end of the investigation. Glucose 
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infusion rate (GIR) was calculated from records of the total amount of glucose infused every 
5-10 minutes. Urine was collected for measurement of urinary glucose excretion during the 
investigation. 
3.4.3.1 Calculations 
First-phase insulin secretion was calculated as area under the curve of serum insulin during 
minutes 0–12 by the trapezoidal rule and was adjusted for the basal insulin level. The glucose 
stimuli will be of importance for the insulin response. As there are some random fluctuations 
in the glucose increase, especially in the beginning of the investigations, first-phase insulin 
responses (min 0-12) were adjusted for any difference in glucose stimuli (calculated as area 
under the curve above baseline) between the baseline and study-end clamps (Kanat, Mari et 
al. 2012).  
Second-phase insulin secretion was calculated accordingly during minutes 12–120. 
Adjustment for glucose stimuli during the second phase was not necessary, as the glucose 
levels were stable during this period of the investigations. The basal insulin level was 
calculated as the mean of insulin measurements at minute -10 and minute 0. Insulin 
sensitivity index (GIR/mean insulin level [I]) was calculated during the last 30 min of the 
investigation as (GIR – urinary glucose excretion rate)/fat-free mass/mean insulin 
concentration x 100. The disposition index (DI), a measure of β-cell function in relation to 
insulin sensitivity, was calculated as insulin secretion x GIR/I during minutes 0–12 and 12–
120, respectively. 
3.4.4 Body composition (study I, II and IV) 
In study I and II, fat-free mass, and total and truncal fat mass were measured by dual-energy 
X-ray absorptiometry (DXA) (Lunar DPX-L x-ray bone densitometer, Lunar Corp., Madison, 
WI). Computerized tomography assessed intra-abdominal fat area (Siemens Somatom Plus, 
Siemens Corp., New York, NY).  
In study IV, a combined bioimpedance and weighing device (Tanita, Tokyo, Japan) was used, 
estimating total body fat and fat-free mass. This simpler technique was applied since fat free 
mass was mainly used in this study to correct clamp calculations for any individual change 
during intervention. 
3.4.5 Physical fitness (study I and II) 
Maximal workload and VO2max were assessed during an exercise test using an electrically 
braked bicycle ergometer. The load was increased in a step-wise manner by 30 W every 
minute until exhaustion. A Jaeger Oxycon software program (Jaeger, Hoechberg, Germany) 
was used to make calculations on expired gases. 
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3.4.6 Step count (study IV) 
A regular step counter was used by the subjects during seven days preceding the 
randomization and study-end visits. Step count per day was used to estimate any possible 
lifestyle change during the study. 
3.4.7 Blood flow assessment and forearm glucose uptake (study III) 
These investigations were done in the morning under fasting conditions and with no caffeine 
or nicotine use during the day of investigation. Percutaneous catheters were inserted into the 
brachial artery in the non-dominant arm for infusions and blood sampling, and in a deep vein 
in the ipsilateral arm for blood sampling. Forearm blood flow (FBF) was measured in both 
arms by venous occlusion plethysmography, a method considered as one of the golden 
standards when investigating vascular function. The method implies using a strain gauge 
applied around the forearm. The venous outflow is obstructed for 10 seconds in the upper arm 
by a cuff during recording, as well as the circulation of the hands by a wrist cuff inflated to 30 
mmHg above systolic blood pressure. The volume of the forearm, assessed by the strain 
gauge, will be proportional to the arterial inflow. Arterial and deep venous blood samples 
were collected for assessment of forearm glucose uptake (FGU). During the investigations, 
the wrist cuff was inflated 2 minutes before blood sampling to avoid contribution from the 
hand circulation. 
3.4.7.1 Calculations 
The mean of 4-8 recordings during 2 min was used for FBF calculation. The ratio between 
the infused and the non-infused arm was utilized for calculations of change in baseline flow. 
FGU was calculated according to the formula: (arterial-venous glucose concentration) x 
blood flow x (1-hematocrit).  
3.4.8 Plasma analyses 
Blood or plasma glucose was determined by a glucose oxidase method (Yellow Springs 
Instrument, Yellow Springs, OH, USA), enabling fast sampling during the clamp 
investigations. Blood glucose values were recalculated to plasma values, if necessary. Plasma 
insulin was measured by an in-house radioimmunoassay method with inter- and intra-assay 
coefficient of variation (CoV) of 11.5–16.9% and 5.8–8.4%, respectively. In study III, plasma 
glucose was analyzed with the SYNCHRON LX system (Beckman Coulter, USA) and 
insulin by an electrochemiluminescence immunoassay (Roche Diagnostics, Germany). 
Plasma proinsulin was measured by a commercial radioimmunoassay (intra- and inter-assay 
CoV of 2.0% and 5.0%, respectively), and with a cross-reactivity for insulin and C-peptide 
<0.1%. HbA1c was analyzed by the high-performance liquid chromatography Mono-S 
method (intra- and inter-assay CoV 0.48% and 2.67%, respectively), which gives absolute 
values ~0.9 lower than the Diabetes Control and Complications Trial method. Mono-S values 
have been re-calculated to DCCT or IFCC (International Federation of Clinical Chemistry) 
units, when appropriate. In Table 2, the values expressed by the tree different standards can 
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be compared. Values in IFCC units (expressed as mmol/mol) are reported in the thesis. 
25(OH)D was analyzed by competitive chemical immunoluminescence (LIAISON, intra- and 
inter-assay coefficient of variation of 5 and 8–11%, respectively). Blood lipids and 
apolipoproteins were analyzed by standard methods at the Karolinska University laboratory 
(Beckman Coulter, USA), as well as free calcium (ABL800 FLEX, Radiometer, Denmark). 
ET-1 was measured by a radioimmunoassay [194]. 
IFCC mmol/mol Mono-S % DCCT % 
31 4.0 5.0 
42 5.0 6.0 
52 6.0 6.9 
63 7.0 7.9 
73 8.0 8.8 
83 9.0 9.8 
Table 2. Conversion between the three different standards for HbA1c. IFCC; International 
Federation of Clinical Chemistry, DCCT; Diabetes Control and Complications Trial 
3.4.8.1 Season-adjusted vitamin D levels (study IV) 
25(OH)D levels were season-adjusted, based on measurements in the SDPP cohort [169]. 
The calendar year was divided in four quarters (Q): November–January (Q1), February–April 
(Q2), May–July (Q3) and August–October (Q4). Q1was set as reference (no correction) and a 
correction value in nmol/L was added or subtracted to the measured value. The corrections 
were Q2 + 6.7, Q3 – 1.9, and Q4 – 13.7. The adjusted values are reported. 
3.4.9 Cell experiments (study III) 
3.4.9.1 Glucose uptake 
Isotope-labeled glucose was used to measure glucose uptake. Muscle biopsies were collected 
in cold PBS supplemented with 1% penicillin-streptomycin solution. Satellite cells were 
isolated and cultured to form myotubes as described [195]. Myotubes were incubated in 
serum free medium overnight before each experiment. ET-1 (10 nM) or vehicle was added in 
the absence or presence of the dual ETA/ETB receptor antagonist bosentan (3 µM) for 24 h. 
Bosentan was always added 30 min before ET-1. Control cells were exposed to vehicle for 
the same length of time. Insulin (60 nM) was added for 30 min, by protocols. Overnight 
serumstarved myotubes (in the presence or absence of 10 nM ET-1) were stimulated with or 
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without insulin in Krebs buffer. Thereafter, cells were incubated with 10 µM 2-
deoxy[3H]glucose (1µCi/ml) for 15 min at 37 °C. Each experiment was carried out on 
triplicate wells. Afterward, cells were rapidly rinsed four times with ice-cold PBS and 
solubilized with 1 ml 0.4 N NaOH. Then, 0.5 ml of lysate was transferred into scintillation 
vials and [3H] measured in a scintillation counter. 
3.4.9.2 Protein expression 
Western blot analysis was used to assess phosphorylation of IRS-1, Akt, AMPK and ERK 
and total expression of Akt and actin. An aliquot of muscle cell lysate (20 µg protein) was 
mixed in Laemmli sample buffer containing β-mercaptoethanol. Proteins were separated by 
7.5% SDS-PAGE, transferred to polyvinylivenediflouride membrane (Millipore, Bedford, 
MA), and blocked in 7.5% nonfat dried milk in Tris-buffered saline with 0.02% Tween 
(TBST) for 2 h at room temperature. Membranes were incubated overnight at 4 °C with 
phospho-specific antibodies against phosphor IRS-1 Ser636 (1:1000), phospho-Akt Ser473 
(1:1000), phospho ERK1/2, p42/44 MAP-kinase Thr202/Tyr204 (1:1000), phospho-AMP-
kinase Thr172 (1:1000), Akt (1:1000), or pan-actin (1:1000, all from Cell Signaling 
Technology, Beverly, MA). After washing in TBST, the membranes were incubated with 
horseradish peroxidase antirabbit IgG for all the target proteins (1:25 000; Bio-Rad, Hercules, 
CA) for 1 h at room temperature, followed by additional washing. Proteins were visualized 
by enhanced chemiluminescence (Amersham, Arlington Heights, IL) and quantified using 
densitometry and Molecular Analyst Software (Bio-Rad, Richmond, CA). 
3.4.10 Gene expression (study II and III) 
3.4.10.1 Study II 
Muscle biopsies were obtained from the m. vastus lateralis in resting state. At the end of the 
study, the biopsies were taken 24–48 h after the last bout of exercise. Quantification of 
mRNA expression of selected genes included VEGF and its receptors 1 and 2, Angiopoietin 1 
and 2, and also PGC-1α. These genes were chosen according to their potential as key factors 
in exercise-induced muscle adaptation. Detection of mRNA was performed on an ABI-
PRISM® 7700 Sequence Detector (Applied Biosystems Inc, Foster City, CA, USA). 
Oligonucleotide primers and TaqMan® probes were designed. 18S rRNA was selected as an 
endogenous control to correct for potential variations in RNA loading (4310893E, Applied 
Biosystems Inc.). All reactions were performed in 96-well MicroAmp Optical plates, using 
the ABI-PRISM® 7700. For every gene, all samples were amplified simultaneously in 
duplicate in one assay run. Relative quantification of the samples was carried out using 
dilution curves for each target gene analogous to a standard curve. The relative distribution of 
the targets was calculated for each individual. A threshold cycle (ΔCt) value was obtained by 
subtracting 18s Ct values from respective target gene Ct values. The relative expression of 
each isoform was then calculated by 2−Δ–ΔCt and presented as arbitrary units. 
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3.4.10.2 Study III 
Myoblasts were cultured in six-well plates and at more than 90% confluence the 
differentiation to myotubes was initiated. Cells were stimulated with vehicle or ET-1 (10 nM) 
for 24 h before harvest. Five days after differentiation, myotubes were washed three times 
with RNase free PBS and harvested directly for RNA extraction (RNAeasy mini kit; 
QIAGEN, Crawley, UK). All RNA was DNase treated before reverse transcription (RQ1 
RNase-free DNase; Promega, Southampton, UK). The mRNA concentrations of target genes 
were determined, and cDNA was prepared from total RNA samples using the TaqMan 
reverse transcription reagent. The quantification of polymerase chain reaction (PCR) products 
was analyzed by Real-Time PCR (TaqMan; Applied Biosystems, Foster City, CA) using the 
comparative cycle threshold method. All samples were analyzed in duplicate. The ABI Prism 
7900 HT Sequence Detection System (Applied Biosystems) was used for analysis. Validated 
primers were purchased from Applied Biosystems (Maastricht, The Netherlands). Data were 
analyzed using GAPDH as a housekeeping gene. 
3.5 STATISTICS 
3.5.1 Studies I, II and IV 
All continuous variables are presented as median (inter-quartile range). Analyses were 
primarily made on relative changes to adjust for baseline differences. Non-parametric 
methods were applied when possible due to small sample size. Thus, the Wilcoxon signed-
rank test was used to test for within-group differences and the Kruskal-Wallis ANOVA or the 
Mann–Whitney U-test was used to analyze differences between groups. The two-tailed Fisher 
exact test was used for categorical variables. In study I (with three different intervention 
groups), Wilcoxon’s rank-sum test was used for pairwise comparisons between groups when 
the overall Kruskal-Wallis ANOVA was significant. Multiple regression analysis was 
performed to adjust for age, sex, and HbA1c at baseline in study I, if necessary. In study II, 
relative change in gene expression was analyzed by multiple linear regression with sex and 
relative changes in insulin sensitivity index, VO2max and HbA1c as independent variables. 
Therapy with acarbose was forced into the models, as we aimed to study the effect of exercise 
alone. All continuous variables were log-transformed before this parametric test. Statistical 
significance was set at a two-tailed P <0.05. No adjustment for multiple testing was 
performed. Data processing was performed using STATISTICA data analysis software 
system (StatSoft Inc., versions 7, 8 and 10). 
3.5.2 Study III 
Data are presented as mean ± standard error of the mean (SEM). A power calculation based 
on a previous study [141] indicated that 10 individuals would suffice to detect a 30% 
difference in FGU at a 5% significance level. Analysis of variance (ANOVA) for repeated 
measurements was used to analyze change in FBF from baseline. Difference between the 
different protocols were evaluated by two-way ANOVA. Protein expression differences were 
assessed by Student´s t test. The significance level was set to P <0.05. 
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3.6 ETHICS 
Participants in all studies were informed about the studies before giving informed consent. 
The investigations were carried out in accordance with the Declaration of Helsinki and were 
approved by the ethics committee of the Karolinska Institute, Karolinska University Hospital 
or the regional human ethics review board in Stockholm. 
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4 RESULTS 
4.1 STUDY I 
4.1.1 Study subjects 
Ninety-four subjects were screened, of which 62 met the inclusion criteria. A total of 14 
subjects were excluded from the per-protocol analysis: seven subjects due to non-compliance 
with the intervention, two subjects due to intercurrent disease and five subjects due to 
dissatisfaction with the allocated intervention or lack of time to participate. Thus, 48 
participants were eligible for the final analysis; exercise only n=17, combined treatment 
n=14, and acarbose only n=17. 
In total, the participants were middle-aged (median 55.5 years) and moderately overweight 
with a median BMI of 27.7 kg/m2. Women constituted 27% of the study population, and by 
chance the sex distribution was uneven between intervention groups, with more women in the 
combined treated group (43%). Median diabetes duration was three years and 60% were 
treated with one OAD, almost evenly distributed between metformin and sulfonylurea. One 
third of the participants had microalbuminuria, but only three subjects had a history of CVD. 
Treatment for hypertension and dyslipidemia were present in 38% and 15% of the 
participants, respectively. 
Glycemic control included a moderately increased median HbA1c of 54 mmol/mol and blood 
lipids demonstrated LDL-cholesterol of 3.3 mmol/l and triglyceride levels of 1.5 mmol/l. A 
selection of basic characteristics, specified per intervention group, are displayed in Table 3. 
 
Table 3. Basal characteristics in the three intervention groups in study I. Values 
are median (interquartile range). HT; hypertension, DL; dyslipidemia, DXA; 
dual-energy X-ray absorptiometry. 
Compliance with the intervention was equal across intervention groups. Attendance at 
training sessions was 86 and 84% in the exercise and the combined treated group, 
Exercise Acarbose+Exercise Acarbose
N (male/female) 17 (14 / 3) 14 (8 / 6) 17 (13 / 4)
Age (years) 54 (50-58) 57 (52-58) 54 (49-58)
N treatment diet/metformin/SU 6 / 4 / 7 7 / 4 / 3 6 / 8 / 3
N HT/DL treatment 7 / 2 6 / 2 5 / 3
BMI (kg/m2) 28.7 (25.6-30.3) 28.7 (26.3-29.6) 27.4 (25.7-28.6)
Waist (cm) 99 (95-106) 103 (99-107) 100 (97-104)
Total fat (kg) DXA 21.7 (17.2-26.5) 23.0 (18.8-31.2) 23.0 (21.1-27.0)
Intraabdominal fat area (cm2) 252 (158-319) 244 (202-292) 227 (173-261)
VO2max/lean weight (ml/min/kg) 42.7 (39.6-47.5) 39.7 (36.2-41.6) 42.3 (40.6-45.0)
Fasting blood glucose (mmol/l) 7.8 (7.5-9.0) 6.7 (5.9-9.5) 7.3 (6.4-7.8)
HbA1c (mmol/mol) 58 (53-63) 51 (42-58) 50 (42-58)
M-value/lean weight (ml/min/kg) 5.1 (3.9-7.2) 6.1 (3.5-9.3) 6.9 (6.3-10.2)
LDL (mmol/l) 3.2 (2.9-3.7) 3.2 (2.8-3.6) 3.5 (3.0-4.0)
Triglycerides (mmol/l) 1,4 (1,2-1,9) 1,4 (0,9-1,8) 1,6 (1,0-2,4)
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respectively, and compliance with acarbose treatment was 95 and 96% in the acarbose and 
the combined treated group, respectively. 
4.1.2 Within group effects 
4.1.2.1 Effects on body composition, physical fitness and glycemic control 
The exercise-alone group demonstrated significant changes in body composition with 
reductions in BMI, waist, total fat and intraabdominal fat-area. VO2max was unchanged but 
maximal workload was slightly enhanced (P = 0.005). The M-value increased by 92% (P = 
0.02), but there was no effect on HbA1c (Table 4). 
Likewise, the combined-treated group showed significant reduction in BMI, waist and 
measures of body fat. Both VO2max and maximal workload increased (P = 0.046 and 0.03, 
respectively) and M-value was augmented by 56% (P=0.002). In contrast to the exercise-
alone group, fasting blood glucose and HbA1c were significantly reduced (P = 0.048 and 
0.002, respectively) (Table 4). 
The treatment with acarbose alone had no significant effects on body composition, physical 
fitness or glycemic control. Fasting proinsulin was reduced significantly (P = 0.009), as well 
as in the combined-treated group (P= 0.01). 
Insulin levels during the clamp investigations (steady-state) did not differ within or between 
the three different intervention groups. 
4.1.2.2 Effects on blood pressure and lipid levels 
Physical training alone resulted in a significant decrease in systolic blood pressure (BP) (140 
to 135 mmHg, P = 0.01), but not in diastolic BP. Lipid levels were not affected. However, 
apolipoprotein(apo)B/apoA1 ratio was decreased (P =0.003) (Table 4). 
The combined treatment resulted in a significant decrease in both systolic and diastolic BP (P 
= 0.001 and 0.02, respectively). Further, reductions were seen in total cholesterol (5.0 – 4.9 
mmol/l, P = 0.04), total triglycerides (1.4 –1.0 mmol/l, P = 0.004), and apoB levels (1.08 –
1.01, P = 0.04). LDL and high density lipoprotein (HDL) cholesterol were unchanged (Table 
4).  
Acarbose treatment alone resulted in significant reductions in systolic and diastolic BP (P = 
0.001 for both), as well as a small decrease in plasma HDL level. No other changes in lipid 
measurements were observed. 
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Table 4. Within group effects of exercise and combined intervention in study I. Values are 
median (interquartile range). Wilcoxon signed-rank test was used. P values >0.2 are listed as 
not significant (ns). DXA; dual-energy X-ray absorptiometry, BP; blood pressure, Apo; 
apolipoprotein.  
4.1.3 Between group effects 
In the total study population, the relative decrease in HbA1c was significantly higher in men 
than in women (P = 0.03). As there was an imbalance in sex distribution across the 
intervention groups, adjustment for sex by multiple regression analysis was performed. 
Analyses showed that HbA1c was significantly lowered when acarbose was added to exercise 
(P = 0.04). Moreover, this regimen resulted in nearly significant reductions in several 
variables, including fasting plasma glucose (P = 0.07), systolic (P = 0.06) and diastolic (P = 
0.07) BP, total fat area (P = 0.08) and apoB/apoA1 ratio (P = 0.09). 
4.2 STUDY II 
4.2.1 Study subjects 
This study was designed to evaluate exercise training. Thus, subjects in study I randomized to 
intervention with exercise training, alone or in combination with acarbose, were qualified to 
participate. Of these subjects, 19 were randomized for muscle biopsy; n=10 on exercise 
training alone and n=9 on the combined intervention with exercise and acarbose. In total 16 
subjects, 4 women and 12 men, completed the study per-protocol. Three participants, all men 
in the combination group were excluded from the analysis: two due to noncompliance and 
one that withdrew at will from the study. Basic characteristics and pre- and post-intervention 
findings are presented in Table 5. 
Before After P Before After P
BMI (kg/m2) 28.7 (25.6-30.3) 28.4 (25.1-29.2) 0.01 28.7 (26.3-29.6) 27.6 (25.7-28.5) 0.004
Waist (cm) 99 (95-106) 99 (92-105) 0.04 103 (99-107) 100 (95-104) 0.008
Total fat (kg) DXA 21.7 (17.2-26.5) 19.3 (15.3-24.6) 0.002 23.0 (18.8-31.2) 20.5 (17.8-29.2) 0.001
Total abdominal fat area (cm2) 454 (321-504) 406 (358-471) 0.02 455 (353-518) 403 (318-470) 0.002
Intraabdominal fat area (cm2) 252 (158-319) 258 (130-284) 0.04 244 (202-292) 222 (154-263) 0.009
VO2max/lean weight (ml/min/kg) 42.7 (39.6-47.5) 46.0 (41.5-47.6) ns 39.7 (36.2-41.6) 44.2 (38.0-46.6) 0.046
Max workload (W) 210 (190-250) 230 (210-270) 0.005 190 (135-230) 190 (150-250) 0.03
Fasting blood glucose (mmol/l) 7.8 (7.5-9.0) 7.4 (6.7-8.5) ns 6.7 (5.9-9.5) 6.4 (5.7-7.7) 0.048
HbA1c (mmol/mol) 58 (53-63) 53 (49-58) ns 51 (42-58) 47 (41-51) 0.002
M-value/lean weight (ml/min/kg) 5.1 (3.9-7.2) 9.8 (4.3-10.3) 0.02 6.1 (3.5-9.3) 9.6 (6.7-13.9) 0.002
Fasting proinsulin pmol/l 22.1 (14.9-26.2)  21.2 (15.0-25.1) ns 20.7 (11.6-26.6) 15.7 (8.6-22.9) 0.01
Systolic BP (mmHg) 140 (135-150) 135 (120-140) 0.01 145 (140-155) 130 (120-135) 0.001
Diastolic BP (mmHg) 83 (75-88) 75 (75-80) 0.16 83 (75-95) 75 (75-80) 0.02
Total cholesterol (mmol/l) 4.8 (4.7-5.3) 4.7 (4.4-5.3) 0.18 5.0 (4.5-5.4) 4.9 (4.3-5.1) 0.04
LDL (mmol/l) 3.2 (2.9-3.7) 3.1 (2.9-3.4) ns 3.2 (2.8-3.6) 3.2 (2.9-3.4) ns
HDL (mmol/l) 1.0 (1.0-1.1) 1.0 (0.9-1.0) ns 1.1 (0.9-1.3) 1.1 (0.9-1.2) 0.09
Triglycerides (mmol/l) 1,4 (1,2-1,9) 1.0 (0.7-1.8) 0.09 1,4 (0,9-1,8) 1.0 (0.7-1.4) 0.004
ApoB 1.11 (1.02-1.20) 1.03 (0.92-1.11) 0.049 1.08 (1.04-1.16) 1.01 (0.92-1.14) 0.04
ApoB/ApoA1 ratio 0.80 (071-0.87) 0.72 (0.61-0.83) 0.003 0.83 (0.64-0.86) 0.77 (0.64-0.88) ns
Exercise (n=17) Acarbose + Exercise (n=14)
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4.2.2 Effects of intervention 
Most clinical features related to T2D were improved by the intervention (Table 5). The two 
different intervention groups only differed in respect to a lower VO2max at baseline in the 
combined treated group (P = 0.02). Otherwise, no significant differences between the 
intervention groups were seen at baseline or in relative change at the study end. 
In contrast to the clinical variables, there was no significant change in expression of any of 
the genes studied by the intervention. 
N (women/men) 16 (4/12)    
Age (yrs) 56 (51-58)    
Diabetes duration (yrs) 4.0 (2.0-5.5)    
N pre-study treatment – diet only/MET/SU 5/6/5     
 Before After P 
Body mass index (kg/m2) 28.3 (25.9-29.6) 27.5 (25.7-28.8) 0.03 
Waist (cm) 99 (96-105) 99 (93-101) 0.01 
Total fat DXA (%) 24.8 (20.9-31.4) 23.6 (20.4-29.8) 0.02 
VO2max/lean weight (ml min-1 kg-1) 40.7 (39.6-47.3) 46.3 (40.5-48.6) 0.005 
HbA1c (mmol/mol) 57 (49-62) 51 (46-55) 0.001 
Fasting plasma glucose (mmol/l) 8.4 (7.2-10.0) 8.2 (6.8-8.8) 0.07 
M/lean weight (mg min-1 kg-1) 5.7 (4.2-7.5) 9.8 (7.2-10.9) 0.004 
M/I (100 x mg min-1 kg-1 pmol-1 l-1) 1.38 (0.91-1.68) 2.35 (1.68-2.92) 0.004 
Table 5. Basic characteristics and pre- and post-intervention findings in study II. Data are 
expressed as median (interquartile range). Wilcoxon signed-rank test was used. MET; 
metformin, SU; sulfonyl-urea, DXA; dual-energy X-ray absorptiometry, M/I; insulin 
sensitivity index. 
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 Beta CIa for beta P Adj. R2b 
VEGF    0.52 
M/I 0.69 0.27 – 1.11 0.004  
HbA1c -0.46 -0.88 – (-0.04) 0.03  
Acarbose treatment 0.19 -0.24 – 0.63 0.4  
     
VEGF receptor-1    0.48 
M/I 0.48 0.04 – 0.92 0.03  
HbA1c -0.63 -1.07 – (-0.20) 0.009  
Acarbose treatment 0.15 -0.30 – 0.60 0.5  
     
PGC-1α    0.34 
M/I 0.40 -0.11 – 0.91 0.11  
Acarbose treatment 0.51 0.005 – 1.01 0.048  
Female sex -0.42 -0.92 – 0.09 0.09  
Table 6. Associations by multiple regression analyses in stud II. Relative changes in 
variables were used and continuous variables were log-transformed prior to analysis. Best 
subset according to Mallow’s Cp was applied. a95% confidence interval. bAdjusted R2 for 
whole model. CI; confidence interval, VEGF; vascular endothelial growth factor, M/I; insulin 
sensitivity index, PGC-1α; peroxisome proliferator–activated receptor γ coactivator-1α. 
4.2.3 Associations by multiple regression analysis 
Adjusted results by multiple regression revealed that the relative change in VEGF expression 
was positively associated with a relative increase in M/I (p = 0.004). In addition, a negative 
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association was found with relative change in HbA1c (p = 0.03). The same pattern was 
demonstrated in VEGF receptor-1 expression, which was positively correlated with an 
increase in M/I (p = 0.03) and a decrease in HbA1c (p = 0.009).  
In contrast, change in PGC-1α expression showed no significant association with M/I (p = 
0.11), and inclusion of HbA1c impaired these regression models. 
No associations between gene expressions and VO2max were found. Furthermore, change in 
expression of the other genes analyzed, i.e. VEGF receptor-2, Angiopoeitin 1 and 2, did not 
show any significant associations with the outcome variables. Acarbose therapy, that was 
forced into the models, differed to exercise alone only in the aspect of a larger relative 
increase in PGC-1α (p = 0.048). 
Data for the significant associations found by multiple regression is shown in Table 6. 
4.3 STUDY III 
4.3.1 Study subjects 
Eleven male subjects were recruited for the in vivo study. Mean age was 61 (± 3) years and 
subjects were overweight with a BMI of 28.4 (±1.6) kg/m2. Six subjects had hypertension and 
two had suffered prior myocardial infarction. Fasting plasma glucose and HbA1c were 5.5 
(±0.1) mmol/l and 38 (±2) mmol/mol, respectively. One subject did not undergo protocol B, 
as he withdrew at will after the second investigation. 
For the in vitro study, eight subjects contributed with muscle biopsy material during elective 
surgery. They were free of metabolic diseases. 
4.3.2 Glucose uptake 
4.3.2.1 Protocol A 
Infusion of ET receptor antagonists increased FGU from 5.1 (±1.0) at baseline to 8.3 (±1.1) 
µmol/min x 1000 ml (P < 0.05) at 60 minutes (Figure 4, panel A). The addition of insulin 
increased glucose uptake additionally to 15.7 (±1.8) µmol/min x 1000 ml (P < 0.001). 
4.3.2.2 Protocol B 
By insulin infusion, FGU was increased from 4.1 (±1.1) at baseline to 12.3 (±1.6) µmol/min x 
1000 ml (P<0.001) at 60 minutes, when steady-state was attained. The FGU reached by dual 
ET-1 blockade in combination with insulin (protocol A) was significantly higher than insulin 
alone (protocol B) (Figure 4, panel B). 
4.3.2.3 Protocol C 
Infusion of insulin in protocol C increased FGU from 7.1 (±0.7) at baseline to 17.8 (±3.0) 
µmol/min x 1000 ml. The addition of ET-1 infusion did not influence FGU (16.5 (±2.0) 
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µmol/min x 1000 ml). Moreover, prolongation of the infusion with ET-1 for 15 min did not 
have any additional effect. 
Neither basal plasma insulin levels, nor concentrations reached during insulin infusion, 
differed between the protocols. 
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Figure 4. Panel A: FGU during NaCl infusion and after 60 min of ETA/ETB infusion in 
protocol A. *P<0.05 by Student´s t test.  Panel B: FGU comparison of protocol A (ETA/ETB 
infusion without and with insulin co-infusion) and protocol B (insulin infusion alone). Two-
way ANOVA including all time points was used. Data are means ± SEM (n=10). Reprinted 
with the kind permission of A. Shemyakin. 
4.3.3 Blood flow 
Basal FBF was similar in the three protocols. 
4.3.3.1 Protocol A 
FBF was increased by 30% with ET receptor blockade infusion (P<0.05). A further increase 
by 16% was measured when insulin was co-infused (P<0.05).  
4.3.3.2 Protocol B 
Insulin infusion alone did not show any impact on FBF.  
4.3.3.3 Protocol C 
ET-1 infusion reduced FBF by 38% when added to insulin infusion. 
4.3.4 Glucose uptake in cultured cells 
Incubation with ET-1 reduced both basal (P <0.05) and insulin-stimulated (P <0.01) glucose 
uptake. This effect could completely be counteracted by co-incubation with bosentan. 
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4.3.5 Insulin signaling in cultured cells 
There was a non-significant trend of augmented insulin-stimulated phosphorylation of IRS-1 
(P=0.13) by ET-1. This trend was inhibited by bosentan. ET-1 did not affect phosphorylation 
of Akt, AMP-kinase or ERK. Akt expression was not affected, neither was mRNA expression 
of GLUT1 and GLUT4 changed after ET-1 incubation. 
4.4 STUDY IV 
4.4.1 Study subjects 
Among the 68 subjects screened for eligibility, 23 did not meet inclusion/exclusion criteria 
and one subject declined to participate. Of the 44 subjects randomized, one subject in the 
vitamin D group was excluded from the study due to initiation of oral corticosteroid 
treatment. Consequently, 43 subjects were available for the intention-to-treat analysis. 
Basic characteristics of the study subjects are shown in Table 7. In total, the study population 
had a balanced sex distribution (47% females) and the median age was 67.3 years. BMI was 
28.5 kg/m2 and waist circumference 101 cm. Altogether, 58% of the study population was 
treated for hypertension and 35% for dyslipidemia. HbA1c was similar in the two groups: 
vitamin D group 43 (38–44) mmol/mol and placebo group 44 (42–46) mmol/mol, 
respectively. Season-adjusted 25(OH)D levels were also similar, 43 (36–50) and 43 (37–54) 
nmol/l respectively, in the vitamin D and placebo groups. Of all participants, 32 had 
prediabetes and 12 subjects were categorized as having diabetes; five randomized to vitamin 
and seven to placebo. Men had a slightly higher baseline 25(OH)D level than women, 
otherwise there were no significant sex differences. 
4.4.2 Effects of vitamin D on outcomes 
Main effects of vitamin D and placebo on study outcomes are presented in Table 8. The 
adjusted 25(OH)D level was doubled in the vitamin D group +42 (32-50) nmol/l, but 
remained unchanged in the placebo group. Concerning the primary end point of first-phase 
insulin secretion, there was a numerical increase in both groups; a tendency in the vitamin D 
group (+26%, P = 0.06) and significant increase in the placebo group (+33%, P = 0.02), with 
no difference between the two groups (P = 0.4). No changes in second-phase insulin secretion 
or insulin sensitivity, either within or between the groups were demonstrated. First-phase 
disposition index (DI) increased in both groups, again with no group difference in 
concordance with first-phase insulin secretion. In the vitamin D group, there was a tendency 
toward an increase in second-phase DI (P = 0.06), but with no statistical difference compared 
with placebo (P = 0.9). 
HbA1c demonstrated a tendency toward a small reduction in the vitamin D group of -1 (-3 to 
1) mmol/mol (P = 0.06), but with no significant difference versus placebo (P = 0.8). Other 
assessments of glycemia were unaltered. Glycemic tolerance category improved slightly in 
both groups, with no group difference.  
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 Overall Vitamin D Placebo 
N (females/males) 43  (20/23) 21  (9/12) 22  (11/11) 
Age (years) 67.3  (64.0–68.5) 67.6  (63.4–68.8) 67.0 (64.7–68.5) 
N IFG/IGT/IFG+IGT/Diaba 10/10/11/12 7/5/4/5 3/5/7/7 
N hypertension/dyslipidemia 
 
25/15 12/5 13/10 
BMI (kg/m2) 28.5 (25.7–29.8) 28.3 (24.5–29.4) 28.6 (26.4–29.9) 
Waist (cm) 101 (95–107) 100 (94–106) 101 (95–112) 
HbA1c (mmol/mol) 44 (41–45) 43 (38–44) 44 (42–46) 
Fasting p-glucose (mmol/l) 6.3 (6.0–6.6) 6.3 (5.5–6.6) 6.3 (6.1–6.6) 
2h p-glucose OGTT (mmol/l) 9.4 (7.5–10.3) 9.3 (7.1–9.7) 9.7 (8.2–10.3) 
25(OH)D (nmol/l) 47 (36–55)  42 (35–55) 47 (42–53) 
25(OH)D (nmol/l) adjustedb 43 (36–54) 43 (36–50) 43 (37–54) 
PTH ng/l 59 (46–67) 62 (50–72) 55 (42–63) 
Triglycerides (mmol/l) 1.3 (0.9–1.8) 1.3 (0.9–1.6) 1.4 (1.0–2.2) 
LDL (mmol/l) 3.3 (2.7–3.8) 3.0 (2.7–3.8) 3.5 (3.1–3.8) 
Step count/day 6300 (4359–8898) 5645 (4277–8316) 7099 (4414–9376) 
Tabel 7. Basic characteristics in study IV. Continuous data are medians (interquartile range). 
aGlycemic tolerance category, bseason-adjusted. IFG; impaired fasting glucose, IGT; 
impaired glucose tolerance, BMI; body mass index, OGTT: oral glucose tolerance test, PTH: 
parathyroid hormone, LDL; low-density lipoprotein. 
The vitamin D group displayed a small increase in fat mass percent, a change being 
significant in group comparison. PTH was reduced by 13% in the vitamin D group, a 
tendency trend when the groups were compared (P = 0.07). Triglycerides decreased nearly 
significantly in the placebo group, this change being significant versus the vitamin D treated 
group (P = 0.02). 
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Vitamin D Placebo Between group  
 Baseline Δ Study end Pa Baseline Δ Study end Pa Pb 
25(OH)D (nmol/l) 
adjustedc 43 (36–50) +42 (32–50) <0.001 43 (37–54) 0 (-7–11) 0.5 <0.001 
            
ISec0–12 
(mU∙l–1∙min) 
 
168 (122–231) +44 (-3–63) 0.06 137 
(51–
363) +45 (-5–136) 0.02 0.4 
           
ISec12–120 
(mU∙l–1∙min) 
 
5689 (2865–8118) +547 
(-1053–
960) 0.79 4509 
(3000–
6508) +56 
(-934–
1006) 0.5 0.8 
           
GIR/I (mg∙min–
1∙kg–1 
∙mU–1∙l∙100) 
 
6.7 (4.7–11.4) +0.3 
(-0.3–
1.4) 0.09 5.9 
(4.6–
9.7) +0.5 
(-0.5–
1.8) 0.3 0.6 
           
DI0–12 
(mg∙kg–1∙100) 
 
1449 (986–1922) +512 
(64–
1082) 0.005 1113 
(389–
2324) +260 (-7–963) 0.006 0.7 
           
DI12–120 
(mg∙kg–1∙100) 
 
34464 (31500–42144) 
+460
8 
(-2345–
12360) 0.06 
2915
7 
(22429–
40285) +4210 
(-4457–
12524) 0.2 0.9 
           
 HbA1c 
(mmol/mol) 43 (38–44) -1 (-3–1) 0.06 44 (42–46) -1 (-3–1) 0.11 0.8 
            
Fasting p-
glucose 
( / ) 
6.3 (5.5–6.6) -0.1 (-0.5–0.4) 0.6 6.3 
(6.1–
6.6) 0.0 
(-0.3–
0.4) 0.9 0.8 
            
2h p-glucose 
OGTT (mmol/l) 9.3 (7.1–9.7) -0.5 
(-1.4–
1.0) 1.0 9.7 
(8.2–
10.3) -0.9 
(-1.5–
1.8) 0.9 0.6 
            
Tabel 8. Effects of vitamin D in study IV. Continuous data are medians (interquartile range). 
aWilcoxon matched pairs test, bMann–Whitney U test on relative changes, cseason-adjusted. 
25(OH)D; 25-OH-vitamin D3, ISec0–12; first-phase insulin secretion, ISec12–120; second-
phase insulin secretion, GIR/I; glucose infusion rate/mean insulin level, DI; disposition index, 
OGTT; oral glucose tolerance test.   
4.4.3 Ancillary analyses in the vitamin D group 
We observed a tendency that basal 25(OH)D levels were negatively correlated to the change 
in 25(OH) D at study-end (r = -0.38, P = 0.09) (Figure 5, panel A). To evaluate if low basal 
25(OH) D levels predicted benefit in terms of first-phase insulin secretion, we performed a 
correlation of change in 25(OH)D and fold change in the outcome. No such association could 
be demonstrated (r = - 0.38, P = 0.34) (Figure 5, panel B). Further exploration of the data, 
where the vitamin D group were divided in high or low basal 25(OH)D levels (limit set to 50 
nmol/l) could not reveal any association by this partition on the change in first-phase insulin 
secretion (P = 0.74) (Figure 5, panel C). Finally, no association between response on vitamin 
D treatment and 25(OH)D level at study-end could be found (Figure 5, panel D). 
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Moreover, there were no associations found between sex and any of the outcomes, and 
omitting subjects with diabetes did not alter the results. 
  
  
Figure 5, panel A–D. Ancillary analyses in the vitamin D group only. R and P values for 
correlations were calculated by Spearman rank R test. Mann-Whitney U test was used for 
group comparison (panel C). 25(OH)D; 25-hydroxy-vitamin D3, ISec0–12; first-phase insulin 
secretion. 
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5 DISCUSSION 
5.1 STUDY I 
The main findings of the study were that in subjects with T2D and mild hyperglycemia, 
twelve weeks of exercise training augmented insulin sensitivity, and improved both body 
composition and blood pressure. Of note, there was no significant effect on glycemic control. 
Importantly, when exercise and acarbose were combined, glycemic control was significantly 
improved, and probably the overall CV risk factor profile. Acarbose treatment alone 
improved blood pressure and decreased the plasma proinsulin levels, considered a marker of 
diminished β-cell stress and improved β-cell function. 
Studies on exercise in T2D have often been rather small, including our study, due to the 
resources demanded for implementation. Consequently, meta-analyses have been performed, 
demonstrating numerically similar effects on glycemic control as in our study [85, 196]. In 
the study of Boule et al., studies with a higher basal HbA1c tended to show greater 
improvements in glycemic control. Our study participants had a fairly mildly elevated Hba1c 
of 54 mmol/mol, making it more difficult to reach an improvement with exercise alone, in 
spite of a marked improvement of 92% in insulin sensitivity. The mode of exercise of 
moderate to high intensity was well tolerated in our sedentary middle-aged subjects. A higher 
intensity training might have attained more pronounced effects [91], but might have induced 
adverse events in our older study population. 
We observed a reduction in plasma proinsulin levels during acarbose treatment, but no effect 
on insulin sensitivity. Theoretically, treatment with acarbose could improve both β-cell 
function and insulin sensitivity by reducing glucose toxicity. However, studies have yielded 
conflicting results. Some evidence points out that the compound could decrease β-cell stress, 
measured as proinsulin or proinsulin/insulin ratio [197-199]. However, short term acarbose 
treatment in older people with IGT did not improve β-cell function [200]. Further, in a study 
on IGT subjects, acarbose improved insulin sensitivity, measured as steady-state plasma 
glucose during an insulin suppression test [201]. In elderly T2D patients acarbose did not 
affect insulin release, but improved insulin sensitivity measured by hyperglycemic clamp 
[202]. On the other hand, in a study in patients with long standing diabetes, acarbose did not 
improve insulin sensitivity [203]. 
Efforts should be made to optimize CV risk factors, including hyperglycemia, and 
combinations of different treatment modalities will often be necessary. Acarbose, as an 
addition to exercise, was chosen since it does not pose any increased risk per se for 
hypoglycemia. Further, there is some evidence supporting CV benefits in subjects with IGT 
and T2D [75, 76], although there has been criticisms about the methods of analysis [77]. It is 
hypothesized that acarbose, by reducing post-prandial glucose excursions, could reduce the 
oxidative stress [79]  thought to be one of the main components driving the development of 
diabetes complications [48]. Gastrointestinal side effects are common with acarbose 
treatment, but did not cause any premature discontinuation in our study. We used a quite 
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rapid dose titration scheme, which has been replaced by a slower scheme in updated 
recommendations [204]. Interestingly, the results of a large trial on CV outcomes are awaited 
in 2018 (Acarbose Cardiovascular Evaluation Trial, ClinicalTrials.gov identifier: NCT 
00829660). 
The strengths of the study comprise in particular the golden standard method used for 
assessment of insulin sensitivity (euglycemic clamp), and the stringent control of the exercise 
intensity. In group comparisons on cardiovascular risk factors, where the effects of the 
addition of acarbose to exercise were evaluated, there were only tendencies in several 
variables, except for the significant effect on glycemic control. However, since most of these 
factors did change in a favorable direction, it is fair to conclude that the CV risk factor profile 
probably was improved with this mode of intervention. The study population is regarded as 
fairly representative of the total diabetes population, based on register data demonstrating that 
50% were treated with diet or OAD and had HbA1c <57 mmol/mol in Sweden at the time 
when the study was performed [205]. 
5.2 STUDY II 
This study demonstrated, in subjects with T2D, that the variation in response to physical 
training, measured as inulin sensitivity and glycemic control, was associated with VEGF 
mRNA expression in muscle. This could constitute a mechanism that contributes to the 
known variation in the individual adaptation to exercise. Supportive of our findings are also 
the association between VEGF receptor 1 expression and the outcomes. This receptor is 
mainly expressed on endothelial cells and participates in mediating the effects of VEGF in 
muscle [108]. 
The changes in gene expression of VEGF and its receptor 1 were associated to change in 
HbA1c, statistically independent of insulin sensitivity. This could infer a positive effect on β-
cell function by exercise training. There are some data supporting this theory in sedentary 
overweight subjects, showing an effect of moderate- to vigorous-intensity training, on 
disposition index during an IVGTT [87]. 
In addition to defects in insulin signaling, the vascular component is probably the other major 
factor behind IR. The number of capillaries is positively correlated to insulin action in muscle 
[31]. This was distinctively shown in mice, where a muscle specific deletion of VEGF 
resulted in a 60% reduction in capillary density, and as a consequence a 40-45% reduction in 
insulin-stimulated glucose uptake in muscle [112]. 
Adding complexity to the underlying mechanisms are the vasoactive properties of insulin, 
including vasodilatation and capillary recruitment. This augments the delivery of insulin and 
glucose to the muscle cells, which in turn increase the insulin-mediated glucose uptake [33, 
206]. It has been proposed that regular exercise improves “vascular fitness” and improves 
capillary recruitment by insulin; this being one mechanism by which insulin sensitivity is 
increased by exercise [206]. 
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We could not find any associations between PGC-1α expression and the degree of response 
to exercise. PGC-1α has mainly been connected to mitochondrial biogenesis, but is also 
thought to be involved in numerous additional adaptive processes [118, 120]. Moreover, in 
mice there are indications that this factor is involved in the regulation of VEGF expression by 
physical training, mediated by the nuclear receptor ERRα [122]. However, in our clinical 
study in humans, we could not detect any impact in physiological adaptation. 
The method of assessing response to exercise gives the possibility to detect significant 
changes in factors, that would not have been noted at the group level. In this study, the 
changes in gene expression by the intervention were not significant when assessing the group 
in total, but became apparent when response was accounted for. 
The number of subjects investigated in the present study was rather small, which could create 
a concern about power. Further, no endpoint effect such as microvascular blood flow or 
capillary density was assessed, which would be desirable in future studies. On the other hand, 
the associations found were statistically strong and advanced techniques were used for 
measurement of the outcomes. We therefore regard that the findings are interesting and 
warrant further research in this area. 
5.3 STUDY III 
The main finding of this study was that dual ETA/ETB blockade increased glucose uptake in 
skeletal muscle, both at the basal and the insulin-stimulated state, in insulin resistant subjects. 
This result supports that endogenous ET-1 is important in regulating muscle glucose uptake. 
Moreover, ET-1 inhibited glucose uptake in cultured skeletal muscle cells by a receptor 
dependent mechanism, indicating a direct impact on muscle cells by ET-1. 
The co-infusion of ETA/ETB blockade and insulin created a more pronounced glucose uptake 
than insulin alone, which is concurrent with previous studies [138, 141]. Additionally, we 
showed that dual blockade enhanced glucose uptake per se. Thus, blockade of the ET-1 
system in subjects with IR augments basal, and facilitates insulin-stimulated, glucose uptake. 
In contrast, infused exogenous ET-1 did not affect insulin-stimulated glucose uptake. This is 
in opposition to earlier findings in healthy individuals [131, 132]. An important difference is 
that we investigated subjects with IR. The ET-1 system has been shown to be activated in IR 
and related conditions [129, 139, 140], and consequently exogenous ET-1 might be of minor 
importance in these states. 
ET-1 demonstrated direct effects on glucose uptake in cultured muscle cells. This finding has 
also been seen in adipocytes [146]. This supports that the influence of the ET-1 system on 
glucose metabolism is beyond that of effects on blood flow alone. The inhibitory impact of 
ET-1 on glucose uptake was entirely reversed by dual receptor blockade, which was in 
conformity with the in vivo results of increased glucose uptake with ETA/ETB blockade 
infusion. 
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The in vitro investigation did not demonstrate any effect on IRS-1 or Akt phosphorylation, in 
contrast to previous studies [130, 145]. Further, we could not detect any impact of ET-1 on 
GLUT1 or GLUT4 expression. However, we did not investigate other important mechanisms 
in glucose transport, such as vesicular trafficking or membrane translocation. Therefore, it is 
possible that ET-1 could affect these cellular phenomena. 
An important observation is that insulin infusion alone did not change FBF. Of note, when 
insulin was added to ETA/ETB receptor blockade, an increase in blood flow was seen. An 
explanation could be that the blockade restores insulin-dependent vasodilatation in IR, which 
would be in agreement with earlier findings [143, 150]. 
There are limitations in our study. First, we did not investigate ET-1 infusion without co-
infusion with insulin. Thus, we cannot make any conclusions of the impact of ET-1 on basal 
FBF or FGU in the study subjects. Second, there was no control group of insulin sensitive 
individuals. The reason was the findings in a previous study, where dual blockade could not 
provoke any effect on vasodilatation in healthy individuals, which was in contrast to IR 
subjects [140]. And finally, w only investigated the effect of dual ETA/ETB receptor blockade, 
and not single ET-1 blockade. We chose this study design since previous studies on similar 
study subjects demonstrated favorable outcomes only after dual blockade [140, 141]. In a 
recent head-to-head study in subjects with T2D and coronary artery disease, the two 
modalities of ET blockade were compared. ETA and dual receptor blockade improved 
endothelium-dependent vasodilatation to the same extent. Additionally, the dual blockade 
increased basal FBF, but ETA-blockade did not [207]. 
5.4 STUDY IV 
This study demonstrated no effect of high-dose vitamin D3 treatment for eight weeks, in 
comparison with placebo, on first-phase insulin secretion in individuals with mildly abnormal 
glucose regulation. Neither could we detect any effects on second-phase insulin secretion, DI 
or in various measures of glycemic control. 
The findings are in analogy with some recent intervention trials. The effect of high-dose 
(mean weekly dose 88 865 IU) vitamin D3 intervention for one year was evaluated in pre-
diabetic subjects with low 25(OH)D levels at baseline (55 nmol/l). No effects could be shown 
on glucose tolerance, nor on insulin secretion or insulin sensitivity with several different 
indices, including OGTT-based calculations. A small but significant difference in HbA1c of 2 
mmol/mol, in favor of vitamin D treatment, was however present at the end of the study 
[208]. In addition, 20 000 IU vitamin D3 weekly for one year in pre-diabetic individuals did 
not improve glycemia, nor HOMA or QUICKI indices in assessment of insulin resistance. 
Analyzing a sub-group with baseline 25(OH) D levels <50 nmol/l gave the same result [209]. 
This study will continue for a total study period of five years. In an Australian study on 
subjects at risk of T2D and with low vitamin D levels, calcium and target-based (25(OH)D 
>75 nmol/l) vitamin D3 treatment for 6 months failed to affect different OGTT-based 
measures of insulin resistance or β-cell function. A post-hoc analysis in the ~50% of the 
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study subjects with pre-diabetes revealed a positive impact on insulin resistance measured by 
HOMA and Matsuda indices [210]. Moreover, giving 50 000 IU vitamin D3 monthly to T2D 
subjects for six months did not improve HbA1c or other glycemic parameters, compared to 
placebo. Moreover, HOMA index of insulin resistance and β-cell function were unaltered. 
Worth considering was a small but significant decrease in HbA1c in severely vitamin D-
deficient subjects (25(OH) D <30 nmol/l). However, this subgroup was very small [211]. 
Finally, a study with a very similar design as ours, but evaluating a vitamin D intervention of 
24 weeks with OGTT-based measures, was recently accepted for publication. The outcome 
results were also in line with our findings, with no impact on glycemic control, β-cell 
function or insulin sensitivity during vitamin D treatment compared to placebo [212]. 
In opposition, intervention with 2000 IU vitamin D3 for 16 weeks in subjects at risk for T2D 
improved first-phase insulin secretion and DI, assessed by a frequently-sampled IVGTT. 
There was a trend toward lower HbA1c level in the vitamin D-treated group compared to 
placebo. The trial also evaluated the effect of calcium supplementation, which had no impact 
on the outcomes [213]. 
In our ancillary analyses, we could not detect that either a low basal vitamin D level, or a 
large elevation of the vitamin D level by the treatment, were associated with the change in 
first-phase insulin secretion. Moreover, the impact of a possible threshold level was 
evaluated. The presence of a threshold level at 65 nmol/l in 25(OH)D has been suggested for 
glucose tolerance and IR [186]. However, the study-end level of 25(OH)D was not related to 
change in first-phase insulin secretion in our study, despite the fact that all but two subjects 
crossed this limit in the vitamin D treated group. 
Limitations of our study include a rather small sample size. In planning the study, no 
adequate data were found that could constitute the basis of a power calculation. Moreover, 
the intervention period of eight weeks could be regarded as rather short to fully investigate 
the effects of vitamin D. On the other hand, study drop-out was minimal (one subject) and the 
risk of a change in lifestyle affecting our outcomes was low. A decrease in PTH were 
observed in the vitamin D group, which could be considered a surrogate for a metabolic 
effect of the vitamin D treatment. The strengths include the golden standard hyperglycemic 
clamp, which to our knowledge has not been used to investigate this area before. 
Taken together, it is unlikely that vitamin D treatment has any substantial effect on glycemic 
control in pre-diabetes or T2D. It is plausible that vitamin D levels constitute a confounder in 
the fairly consistent observational findings of an association with T2D. Interestingly, in a 
Swedish prospective cohort study on individuals with T2D, low baseline 25(OH)D levels in 
men remained related to a higher all-cause mortality after adjusting for several CV risk 
factors, including HbA1c. In women, high PTH levels, but not vitamin D levels, showed an 
association with total mortality [214].  
It is not entirely excluded that vitamin D intervention for a longer period of time might have a 
small impact on glycemic control, or could prevent T2D development in subjects at risk. 
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Interestingly, results of a study are awaited in 2017 that hopefully can elucidate these 
remaining questions [215]. 
6 CONCLUSIONS 
Exercise training improved insulin sensitivity and body composition in mild T2D. With the 
addition of acarbose treatment, improved glycemic control was also attained. The general 
cardiovascular risk factor profile was probably improved more with the combination therapy 
than with exercise alone. 
The individual response to exercise training in terms of improved insulin sensitivity was 
associated to change in VEGF expression. Moreover, decrease in HbA1c also showed this 
association. The individual adaptation to physical exercise can in part be dependent on VEGF 
expression, adding a potential target to influence IR. 
ET-1 infusion decreased blood flow but had no effect on glucose uptake. Dual ETA/ETB 
blockade increased glucose uptake, both with and without inulin stimulation, and increased 
blood flow. In cell cultures, ET-1 impaired glucose uptake, an effect that could be 
counteracted by ET receptor blockade. This receptor-dependent mechanism by ET-1 on 
glucose metabolism could constitute a possible drug target. 
Intervention with vitamin D had no effect on β-cell function, insulin sensitivity or glycemic 
control. Our findings do not support treatment with vitamin D in subjects with pre-diabetes or 
type 2 diabetes, neither in those with low vitamin D levels. 
7 FUTURE PERSPECTIVES 
Exercise training is obviously a powerful treatment option T2D. In this era of personalized 
medicine, it would be an importat advantage to be able to predict which individuals that 
would benefit the most by exercise intervention. Then great efforts should be made to provide 
this probably highly cost-effective treatment to these patients. 
Acarbose has not been used frequently in diabetes treatment in Sweden. I believe that the 
criticism of the data on CV protection had an impact. But there are some promising findings 
with the compound, and if the awaited outcome study will show benefits with the treatment, 
more mechanistic studies on especially post-prandial hyperglycemia seem warranted. 
Moreover, acarbose could be an alternative in other group of patients, such as type 1 diabetes 
and diabetes in pregnancy. 
The vascular contribution in IR is interesting. This could constitute possible drug targets, not 
the least since there is a lack in pharmacological options in affecting IR. The use of bosentan 
has been limited due to adverse effects, especially fluid retention. If other compounds can be 
developed, this would consequently be of interest for clinical trials.  
The 'training pill' is still awaited. Noteworthy, reservatrol (a substance found in red wine) has 
shown to have some promising effects on IR, perhaps mediated by an effect on AMP-kinase, 
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PGC-1α and mitochondrial function [216]. If a compound with low toxicity could be found to 
influence these pathways, this would have a huge impact diabetes treatment. 
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